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ABSTRACT

Voluntary Oral Methamphetamine reveals susceptibilities to spatial memory deficits,
decreased dopamine marker expression and increased neuroinflammation in the
hippocampus of male and female mice
By
Jorge Andres Avila
Advisor: Peter A. Serrano

Methamphetamine is an addictive illicit psychostimulant that produces lasting
neurochemical and behavioral changes. The mechanisms underlying these deficits have been
characterized in animal models using extremely high doses. Currently, better translational
models are needed to understand the onset and progression of these deficits that more accurately
reflect the gradual and voluntary dosing parameters as chosen by an abuser. To that end, a new
model of methamphetamine administration, labeled Voluntary Oral Methamphetamine
Administration (VOMA), offers a means to examine the progression of neurotoxicity, behavioral
deficits, and the addiction process through a voluntary consumption framework.
Female populations show consistent vulnerabilities to methamphetamine, including
greater severity of abuse, and greater shifts in psychological health. Females also show increased
neurochemical susceptibilities during abstinence from methamphetamine, exhibiting increased
grey-matter loss compared to controls. The mechanisms underlying these female-specific
susceptibilities to methamphetamine are unknown.
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The overall GOAL of these studies was to establish a voluntary methamphetamine
administration model in mice that recapitulates the cognitive and neurochemical deficits shown
with previous models to further our understanding of the long-term susceptibilities of at-risk
populations, including adolescent and female subjects.
Rodents can exhibit drug-preference and drug-seeking behaviors, and methamphetamine
challenges can reproduce the behavioral and neurochemical deficits that human addicts show.
However, it is unclear if mice would voluntarily consume methamphetamine, and what effects
this administration design would produce in this mice. Thus, the studies presented in this
dissertation characterized the utility of the VOMA model to produce 1. naturalistic
methamphetamine consumption 2. behavioral deficits and 3. neurochemical changes. This was
done in an effort to understand the 4. mechanisms underlying adolescent- and female-specific
vulnerabilities to the drug.
To achieve our GOAL, we carried out three (3) specific aims:

Specific Aim 1: Determine the utility of Voluntary Oral Methamphetamine
Administration (VOMA) to produce behavioral and neurochemical deficits as seen in
previous models [Chapter 2]
In modeling MA abuse with rodents, researchers have developed paradigms that inject
neurotoxic or binge doses in mice that are 10 times higher than the lower limits we have
characterized in our models 1 (reviewed in2). Previous work in this line of research has found that
two (2) 30mg/kg MA doses can acutely increase spatial working-memory performance but also
increase spatial working-memory errors in the long-term. These effects were correlated to
decreased DA and synaptic plasticity maker expression in the hippocampus 1. These prior studies
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have contributed significantly to our understanding of the mechanisms underlying MA toxicity 2,
but offered very little in understanding the voluntary nature of methamphetamine administration.
In order to characterize the utility of VOMA in producing MA consumption that produced
cognitive and neurochemical deficits, we combined a spatial cognition design with a drug
administration design as follows: mice were randomly assigned to either a water/control group or
MA for 28 consecutive days. To carry out voluntary oral MA administration (VOMA) in mice,
MA was mixed into a palatable sweetened oatmeal flake that mice were drawn to and ingested
orally. Mice were allowed to consume MA throughout a 3-hour administration period, within 15
min intervals. Following 28-days of VOMA, mice were sacrificed, and tissues were collected.
We found that VOMA:
(1) Decreased working-memory and reference-memory performance of male mice on the
radial arm maze. These behavioral deficits were observed after the 28-day drug
administration period over a 2-week abstinence period.
(2) Increased neurotoxicity in the hippocampus, as observed through lower dopamine
marker expression, increased neuroinflammation, and lower synaptic-plasticity marker
expression.
Overall, these results indicate that VOMA can produce the behavioral and the
neurochemical deficits observed in previous animal models as well as in human methamphetamine
addicts. Additionally, that the molecular deficits were observed in the hippocampus highlights the
utility of the model to easily characterize correlative cognitive behaviors and the underlying
molecular shifts.
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Specific Aim 2: Characterize the role of abstinence in perpetuating
methamphetamine-induced deficits using VOMA [Chapter 3]
MA abuse can produce long-term cognitive impairments in abstinent individuals3-5 but
other studies have shown that long periods of abstinence can improve the recovery of decision
making-skills and emotional symptoms6. This may help individuals to avert relapse and yet,
other reports indicate that relapse can occur after abstinence7, as a result of exposure to specific
environmental cues8. The neurochemical pathways affected by abstinence from MA are also
unclear. An understanding of the progression of behavioral and neurochemical changes produced
by MA abuse and by abstinence would provide pharmacological targets to aid in recovery from
addiction.
In order to characterize the role of abstinence in producing MA-induced behavioral and
molecular deficits, we used an acute VOMA design to do the following: put adolescent mice
through cognitive assessments directly after 14 days of MA exposure and after a prolonged
abstinence period. Tissue was collected directly after VOMA and after a 4-week abstinence period.
We found that VOMA:
(1) Produced a transient sensitization to MA as seen through behavior analyses in the drugcontext
(2) Produced an acute spatial working-memory deficit on the RAM directly after VOMA
We found that abstinence:
(1) Did not produce long-term working-memory, reference learning, nor retention deficits
on the RAM
(2) Increased expression of neuroinflammatory markers in the hippocampus
(3) Modulated expression of monoamine proteins in the hippocampus
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Overall, these results indicate that abstinence from VOMA acutely affects behavioral
performance that is ameliorated by abstinence. Further, abstinence produces neurochemical
changes not observed directly following VOMA. This demonstrates that even acute MA exposure
is sufficient to produce molecular changes in the brain despite not manifesting in behavior. This
highlights the susceptibility of the adolescent brain to acute MA exposure and provides new
avenues for pharmacological studies aimed at preventing MA-induced deficits.

Specific Aim 3: Characterize the sex-differences in behavior and neurochemistry
following escalating dose of methamphetamine using VOMA [Chapter 4]
Previous work has shown that females exhibit susceptibilities to psychostimulant-addiction
9-12.

It has been reported that methamphetamine use in female populations can be attributed to

factors including weight loss, desire for increased energy and work output, and decreased
exhaustion 13-14. Data on drug-rehabilitation admissions show that young female participants are
admitted at higher rates compared to males

15.

One hypothesis for sex differences in

psychostimulant addiction highlights estrogen’s facilitation of neuronal and behavioral
development of drug addiction processes in the brain. 16-18. However, this idea remains untested.
Additionally, previous work has shown that escalating doses of methamphetamine have
intrinsic neuroprotective qualities that protect the brain and behavior from a chronic administration
of the drug. The nature and source of this neuroprotection is unclear, but previous work has shown
that this phenomenon occurs in binge injection models,

19-20,

associated with decreases in

methamphetamine binding to DAT and decreases in the resulting DA availability in the synapse.
However, the underlying mechanisms that produce this change in DA sensitivity remain unknown.
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To test how female subjects respond differentially to VOMA, we modified our
administration design to include a 10-day escalation period, wherein mice would receive gradually
escalating doses of and access to methamphetamine prior to receiving the maximum access and
dose. We hypothesized that that this administration design would produce the maximal voluntary
consumption over a shorter (18-day) period and produce the maximal behavioral and molecular
deficits that could be observed.
We found that Escalation-VOMA:
(1) Decreased working-memory of female mice on the radial arm maze shortly after the
conclusion of VOMA. This deficit was not observed in male mice that were placed into
VOMA.
(2) Discrete shifts in neuroprotective signaling (D1, ERα and Akt/GSK3β pathway) in the
hippocampus and nucleus accumbens of female mice after a 2-week abstinence period.
Male mice that underwent VOMA did not exhibit any molecular changes.
Overall, this study showed that through VOMA, and with the aid of an escalating-dose
design, we are able to observe sex-differences in the behavioral and neurochemical changes that
methamphetamine can produce. Interestingly, we also observed a previously reported
neuroprotective effect of escalating doses in male subjects, but not in females. Our molecular
investigations will provide future direction in basic research and clinical endeavors to target
methamphetamine addiction.

Conclusion: The novel VOMA design has provided a more naturalistic approach to
investigating the behavioral and molecular deficits produce by methamphetamine and abstinence
during adolescence. With this model, we have successfully characterized longer-term
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susceptibilities in mice than previous studies have shown. Furthermore, it has provided new
insights into the sex-differences surrounding meth-abuse, including the role of neuroprotective
pathway signaling as markers for susceptibilities/resilience to methamphetamine abuse.
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CHAPTER 1: INTRODUCTION
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1.1

Methamphetamine addiction: The negative consequences on behavior and cognition

Methamphetamine (MA) abuse has an approximate $23.4 billion annual cost to society 21. Of this
total, 71% can be attributed to intangible costs, including psychological stress and deficits.
Studies on MA’s effects on cognitive and psychological functions have increased in the last 10
years 22, with conflicting clinical studies showing both cognitive enhancements and cognitive
deficits after acute exposure to MA. Conversely, clinical studies on chronic MA exposure
indicate long-lasting and progressive cognitive decline in these MA abusers 23-24 Furthermore,
the addictive and neurotoxic nature of the drug produces long-term cognitive impairments in
abstinent individuals 4, 22-23. Thus, the time course of MA abuse and abstinence may play a major
role in the progression of cognitive dysfunction. Chronic MA users develop cognitive deficits in
sustained attention, episodic memory, information processing, and impulse control 25-28. Finally,
hallucinations and cognitive impairment are clinical symptoms of MA psychosis in patients who
show a sensitization to MA 29. Thus, research should seek to characterize the milieu of effects
that MA can have on cognition, distinguishing between cognitive effects of acute vs. chronic MA
exposure, as well as the specific cognitive capacities that are affected. Methamphetamine (MA)
abuse is a costly and detrimental health risk in the U.S. and abroad. In the U.S., the number of
individuals who reported abusing MA in 2012 was approximately 1.2 million people (4.7 percent
of the population) 30. Amphetamine-type stimulants (ATS) now rank second only to cannabis as
the most common illicit drugs used worldwide, representing approximately 34 million users 31.
North America continues to be a significant market for ATS, particularly amphetamine and
methamphetamine 32. Based on these statistics, it becomes increasingly important that we
understand the risk factors associated with MA addiction, and develop new animal models to
better address treatment outcomes for addicts. It is well known that MA abusers show a long-
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lasting reduction in dopamine terminals and transporters, both of which increase the risk for
Parkinson’s Disease 33-34. Chronic MA abuse also results in neurodegeneration of frontal cortex,
midbrain regions and hippocampus, which are all associated with memory deficits 35.
Additionally, an increase in markers of neuroinflammation, including activated microglia was
reported in MA abusers 36. Several animal studies have recapitulated many of these
neurochemical and behavioral characteristics associated with MA abuse [reviewed in 2; briefly
summarized in ]. Many animal studies show that neurotoxic or binge-dosing regiments of MA
produce rapid increases in microglia 37 and glial fibrillary acidic protein (GFAP) levels within
the striatum and hippocampus

38-40

shortly after administration.
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Table 1: Molecular changes characterized in animal models of MA abuse. An overview of
neurotoxic, dopaminergic and glutamatergic changes in the striatum and hippocampus of rodents
highlighting the MA administration methods, the molecular markers used, and the timing of
tissue collection.

MA Administration
Protocol

Tissue
Collection

Brain
region

Study

BRDU/cell counts

I.P. 30mg/kg

12 weeks

Striatum

41

TUNNEL
staining/cell counts
Cresyl Violet
stain/cell counts
GFAP IHC/Cell
counts

I.P. 10mg/kg, 20mg/kg,
30mg/kg, 40 mg/kg

24 hrs

Striatum

42

I.P. 30mg/kg

24 hrs

Striatum

42

10mg/kg x4

1 wk

Striatum

43

Neurotoxicity Effect

Markers/Method

Increased pyknotic nuclei
Increased apoptosis
Decreased cell density
Increased astrocytosis
No increases in
neurodegeneration

Fluorojade C IHC

6d Escalating doses (1025mg/kg) + 30mg/kg on d7

24 hrs

Striatum

44

Dopaminergic dysregulation

Markers/Method

MA Administration
Protocol

Tissue
Collection

Brain
region

Study

Decreased DARPP-32 neurons

DARPP-32 IHC/cell
counts

I.P. 30mg/kg

24 hrs

Striatum

42

Decreased D1 receptor levels

D1/Western Blot

I.P. 30mg/kg x2

6 wks

Hippocampus

1

Increased DAT levels

DAT/Western Blot

I.P. 30mg/kg x2

6 wks

Hippocampus
+ Striatum

1

Decreased DAT levels

DAT/Western Blot

10mg/kg x4

1 wk

Striatum

43

Decreased TH levels

TH IHC/Optical
density

10mg/kg x4

1 wk

Striatum

43

Glutamatergic
dysregulation

Markers/Method

MA Administration
Protocol

Tissue
Collection

Brain
region

Study

I.P. 30mg/kg x2

6 wks

Hippocampus

1

I.P. 30mg/kg x2

6 wks

Striatum

1

24 hrs

Striatum

44

24 hrs

Striatum

44

Increased NMDA receptor levels
Decreased AMPA and NMDA
receptor levels

GluN2B/Western
Blot
GluA2 +
GluN2B/Western
Blot

6d Escalating doses (1025mg/kg) + 30mg/kg on d7
6d Escalating doses (1025mg/kg) + 30mg/kg on d7

Increased AMPA receptor levels

GluA2/Western Blot

Increased NMDA receptor levels

GluN2B/Western
Blot

Decreased AMPA receptor levels

GluA2/Western Blot

30mg/kg

24 hrs

Hippocampus

38

GluN1/Western Blot

6d Escalating doses (1025mg/kg) + 30mg/kg on d7

24 hrs

Hippocampus

38

Decreased NMDA receptor levels
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1.2

The Neurocircuitry of Methamphetamine addiction: The vulnerability of the

Hippocampus
MA is known to directly affect the monoamine neurotransmitter systems 45. Clinical MA abusers
show deceased density of dopamine transporters (DAT) in the striatum and frontal cortex 33, 46-47,
two regions associated with reward processing and drug addiction

48-50.

However, chronic MA

abuse also results in neurodegeneration of frontal cortex, midbrain regions and hippocampus and
is associated with memory deficits

35.

Additionally, the ventral hippocampus-ventral striatum

circuit is known to participate in stimulant-induced expression of drug addiction behaviors

50,

suggesting that stimulant abuse could alter hippocampal-dependent behaviors through changes in
hippocampal synaptic plasticity. In fact, a recent study has found that neurotoxic doses of MA can
alter DA and glutamate marker levels in the hippocampus, affecting hippocampal-dependent
behaviors 1. Additional evidence of hippocampal vulnerabilities to MA come from proteomic
studies that found the drug to increase major apoptotic, inflammatory, and neurodegenerative
pathway activity in this region 51. Activation of inflammatory and degenerative pathways in the
brain are hypothesized to underlie the progression and development of neurodegenerative diseases
like Alzheimer’s and Parkinson’s disease 52. Thus, serving a variety of roles within drug abuse and
exhibiting many important molecular vulnerabilities, the hippocampus is emerging as a pivotal
region in the study of MA abuse and addiction.

1.3

The acute and lasting effects of Methamphetamine abuse on the brain

MA can produce a variety of neurobiological effects once it has been consumed. The primary
mechanism of action of MA in the brain is to act on dopamine (DA) and serotonin (5-HT)
synapses. MA spills neurotransmitter into the cytosol via interactions with VMAT2 (synaptic
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vesicle channel pump), followed by reversing DAT function and decreasing SERT activity (DA
and 5-HT reuptake transporters (respectively)), leading to increased neurotransmitter release and
post-synaptic receptor activation 45. These processes underlie the euphoria produced by MA.
However, these processes become dangerous very quickly. Once DA has been displaced to the
cytoplasm, it rapidly auto-oxidizes to form reactive oxygen species (ROS) that include
superoxide radicals, DA quinones 45. Increased MA-dependent ROS formation has been linked to
decreased tryptophan hydroxylase (TPH) (5-HT rate-limiting enzyme) activity in the
hippocampus through oxidation of TPH as early as 1 hour after MA treatment 53 and linked to
increased tyrosine hydroxylase (TH) (DA rate-limiting enzyme) activity and DA synthesis that
contribute to MA-induced neurotoxicity and damage to DA terminals. 54. Further evidence of
ROS-induced damage from MA comes from 55 who showed that administration of neurotoxic
doses of MA to rats caused DA oxidation to DA-quinones that bind to cysteinyl residues on
proteins, increasing protein cysteinyl-DA levels in the striatum. Protein oxidation in the brain
can result in various signaling, homeostatic and even behavioral deficits, as revealed by studies
of protein oxidation using amphetamine derivative, ecstasy (MDMA), and ethanol 56. These
mechanisms can cause DA terminal degeneration leading to reductions in dopamine availability,
which can increase the risk of Parkinson’s Disease and its associated symptoms 33-34. Studies
have also elucidated the effects of MA on the glutamate system, reviewed in 57-58. MA
synergistically increases DA terminal depletions through glutamate activity 59, but also can
increase glutamate release via reactive-nitrogen-species activation 60, and can cause glutamate
excitotoxicity and calpain-dependent proteolysis via AMPA receptor activation 61 in the striatum.
More recent studies have shown that neurotoxic doses of MA can cause decreases in AMPA
receptor and synaptic scaffolding and trafficking markers, PSD-95 and PKMζ, in the
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hippocampus 1 which could underlie the spatial learning and memory deficits revealed in the
same studies. These MA-induced effects on the DA and glutamate systems can have far-reaching
effects on cognitive functioning and require detailed investigations in behavioral models of MA
abuse (Fig 1).
The effects of MA on the brain and behavior depend on how similar its chemical structure is to
DA, which allows the drug to enter DA terminals through DAT reuptake 45 or through lipid
membranes due to the high lipophilic nature of the compound 62-63. Once inside the axon, MA
can sequester VMAT2, also likely due to the similarity to DA, and through pH changes in the
synaptic vesicle microenvironment 64 spills DA from synaptic vesicles into the cytoplasm 45.
Through interactions with DAT, MA can induce reverse transport of cytosolic DA into the
synaptic cleft 45. This increased availability of DA at the synapse is what allows for increased
DA release, and once the MA-dependent increases in DA release occur in the nucleus accumbens
and prefrontal cortices (brain regions that compute reward), the individual feels euphoria. This
mechanism is understood to be the underlying end of MA abuse by addicts.

Once DA has been displaced to the cytoplasm by MA and VMAT2-depedent mechanisms, it
rapidly auto-oxidizes to form reactive oxygen species (ROS) that include superoxide radicals,
hydroxyl radicals, hydrogen peroxide and DA quinones 45. Increased MA-dependent ROS
formation has been linked to decreased tryptophan hydroxylase (TPH) (5-HT rate-limiting
enzyme) activity in the hippocampus through oxidation of thiol groups of TPH as early as 1 hour
after MA treatment 53. Further evidence of ROS-induced damage from MA comes from 55 who
showed that administration of neurotoxic doses of MA to rats caused DA oxidation to DA
quinones that bind to cysteinyl residues on proteins, which lead to an increase in protein
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cysteinyl-DA levels in the striatum. These increases in oxidation of DA occurred only under
conditions resulting in neurotoxicity, suggesting that the oxidation of DA may play a major role
MA-induced damage to DA terminals. It is well known that MA abusers show a long-lasting
reduction in dopamine terminals and transporters both of which increase the risk of Parkinson’s
Disease 33-34.

There is evidence that links the 5-HT transporter (SERT) to MA-induced damage of 5-HT
terminals. A number of SERT inhibitors, including fluoxetine, have been shown to block MAinduced reductions in TPH activity and prevent 5-HT depletion in the striatum, hippocampus and
cortex 45 suggesting a role for SERT in MA-induced 5-HT terminal degeneration. Clinical
Positron emission tomography (PET) studies have shown decreased levels of serotonin
transporter (SERT) in the orbitofrontal and occipital cortices in individuals who were currently
abstinent from MA 65-66. These individuals also showed increased aggression, highlighting how
MA abuse and addiction can alter emotional and psychiatric health.

MA neurotoxicity is also driven by excitotoxic damage following glutamate release and
activation of glutamate receptors 67. MA-induced glutamate release in the striatum is thought to
be initiated by DA D1 receptor-dependent stimulation of striatonigral GABAergic pathway that
causes increases in GABA release in the substantia nigra pars reticulata, inhibition of
nigrothalamic GABAergic outflow via activation of GABAA receptors, and followed by
disinhibition of thalamocortical afferents with resulting increases in striatal glutamate release 68.
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Microglia are the resident immune cells in the brain that protect against injury and long-term
damage 69. In the healthy brain, microglial cells exist in a quiescent state and they monitor the
neuronal environment for any signs of injury and assist in housekeeping duties as it becomes
necessary 69-70. However, in response to trauma, injury, or disease, microglial cells increase in
size, migrate to the site of the injury, and undergo a series of signaling and phagocytic events
that enable them to respond adequately to begin the process of repair 69-70. While microglial
activation is essential for immune responses and restoration of normal neuronal function, the
persistent or unceasing activation of microglial cells can result in neurotoxic consequences.
Indeed, multiple lines of evidence have suggested that activated microglia release a variety of
cytokines, reactive oxygen and nitrogen species and PGs that are known to cause neuronal
damage during responses to injury 70-71 and, therefore, might be involved in neurodegeneration
through pro-inflammatory processes. Importantly, prostaglandin-J2 (PGJ2), the most neurotoxic
of all PGs, is a direct product of pro-inflammatory activity via COX-2 dependent mechanisms,
and can feed-back onto COX-2 pathways to upregulate pro-inflammatory activity 72. A goal of
this proposal is to determine the levels of PGJ2 in VOMA mice, in order to delineate the state of
inflammatory processes in the brain due to MA abuse. In fact, an increase in markers of
neuroinflammation, including activated microglia has been reported in MA abusers 36. Another
report shows that the pro-inflammatory marker COX-2 increases in the striatum 73 occur as a
result of MA use and is an obligatory factor in the neurotoxicity induced by the drug.

9

Figure 1. Model of Methamphetamine-induced effects on the brain and cognition. Neuroglial activation potentiates a neuroinflammatory response that can perpetually affect synaptic
plasticity and in turn cognition.
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1.4

The role of escalating exposure on Methamphetamine-induced effects

Because binge or bolus neurotoxic MA administration are not thought to model the typical
pattern of human MA use, several groups of investigators focused their attention on using
escalating MA dosing to investigate its effects on the brain. For example, one study administered
MA on an escalating dose regimen, where injections were given 3x/day for 13 days starting at
0.1 mg/kg bw (s.c.) and increased by 0.1 mg/kg with every injection, so that on the 13th day, the
animals received 3.9 mg/kg 74.This was done with the idea that some addicts would gradually
escalate their doses and frequency of intake45. Assessing the neurochemical deficits associated
with MA in this dosing paradigm potential protective effects that occur as a result of repetitive
dosing spread out across days. These reports reveal that differing doses across consecutive days
may provide some neuroprotection and/or delay the long-term damage 19-20.

1.5

Susceptibility in adolescent and female populations to Methamphetamine abuse

A significant body of literature has shown that select populations, females
76,

9-12

and adolescents 75-

exhibit susceptibilities to psychostimulant-addiction. It has been reported that MA use in female

populations can be attributed to factors including weight loss, desire for increased energy and
work output, and decreased exhaustion

13-14.

Data on adolescent trends of abuse are sparse, but

available studies suggest complex psycho-social dynamics at play in the progression of MA abuse
in these populations

77.

Furthermore, data on MA treatment admissions show that younger age

groups are admitted at a higher rates and that in these younger groups, females are admitted at
higher rates compared to males 15. Mechanistic studies on the effects of MA in these populations
indicate neurobiological resilience to neurotoxic regimens of MA

78-79,

although the underlying

mechanisms of this resilience in adolescents remain unclear 80. One hypothesis for sex differences
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in MA abuse highlights estrogen’s facilitation of neuronal and behavioral development of drug
addiction processes. 16-18. Models to explain the susceptibility of adolescent psychostimulant abuse
are focusing on developmental trajectories of cortico-limbic circuits and the impact of
environmental stress on psychosocial-dependent behavioral dynamics 81-82. However, not much is
known about the long-term trajectories of hippocampal behaviors and molecular profiles stemming
from MA abuse in these populations.
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2.1 Abstract
Methamphetamine (MA) is an addictive drug with neurotoxic effects on the brain producing
cognitive impairment and increasing the risk for neurodegenerative disease. Research has
focused largely on examining the neurochemical and behavioral deficits induced by injecting
relatively high doses of MA [30 mg/kg of body weight (bw)] identifying the upper limits of MAinduced neurotoxicity. Accordingly, we have developed an appetitive mouse model of voluntary
oral MA administration (VOMA) based on the consumption of a palatable sweetened oatmeal
mash containing a known amount of MA. This VOMA model is useful for determining the lower
limits necessary to produce neurotoxicity in the short-term and long-term as it progresses over
time. We show that mice consumed on average 1.743 mg/kg bw/hour during 3 hours, and an
average of 5.23 mg/kg bw/day over 28 consecutive days on a VOMA schedule. Since this
consumption rate is much lower than the neurotoxic doses typically injected, we assessed the
effects of long-term chronic VOMA on both spatial memory performance and on the levels of
neurotoxicity in the hippocampus. Following 28 days of VOMA, mice exhibited a significant
deficit in short-term spatial working memory and spatial reference learning on the radial 8-arm
maze (RAM) compared to controls. This was accompanied by a significant decrease in memory
markers protein kinase Mzeta (PKMζ), calcium impermeable AMPA receptor subunit GluA2,
and the post-synaptic density 95 (PSD-95) protein in the hippocampus. Compared to controls,
the VOMA paradigm also induced decreases in hippocampal levels of dopamine transporter
(DAT) and tyrosine hydroxylase (TH), as well as increases in dopamine 1 receptor (D1R), glial
fibrillary acidic protein (GFAP) and cyclooxygenase-2 (COX-2), with a decrease in
prostaglandins E2 (PGE2) and D2 (PGD2). These results demonstrate that chronic VOMA
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reaching 146 mg/kg bw/28d induces significant hippocampal neurotoxicity. Future studies will
evaluate the progression of this neurotoxic state.
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2.2 Introduction

Methamphetamine (MA) abuse is a costly and detrimental health risk in the U.S. and abroad. In
the U.S., the number of individuals who reported abusing MA in 2012 was approximately 1.2
million people (4.7 percent of the population) 30. Amphetamine-type stimulants (ATS) now rank
second only to cannabis as the most common illicit drugs used worldwide, representing
approximately 34 million users 31. North America continues to be a significant market for ATS,
particularly amphetamine and methamphetamine 32. Based on these statistics, it becomes
increasingly important that we understand the risk factors associated with MA addiction and
develop new animal models to better address treatment outcomes for addicts. It is well known
that MA abusers show a long-lasting reduction in dopamine terminals and transporters, both of
which increase the risk for Parkinson’s Disease 33-34. Chronic MA abuse also results in
neurodegeneration of frontal cortex, midbrain regions and hippocampus, which are all associated
with memory deficits 35. Additionally, an increase in markers of neuroinflammation, including
activated microglia was reported in MA abusers 36. Several animal studies have recapitulated
many of these neurochemical and behavioral characteristics associated with MA abuse [reviewed
in 2]. Many animal studies show that neurotoxic or binge-dosing regiments of MA produce rapid
increases in microglia 37 and glial fibrillary acidic protein (GFAP) levels within the striatum and
hippocampus

38-40

shortly after administration.

While there are many MA paradigms for rodents currently used, what is needed is a model that
capitalizes on the voluntary MA consumption without the need for conditioning to administer the
drug or surgery that can restrict the types of behavioral assessments used. Here we provide data
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on a voluntary oral methamphetamine administration (VOMA) model useful for determining the
progressive nature of voluntary abuse-associated neurotoxicity in a rodent model. Our goal was
to assess the effectiveness of this VOMA model in producing hippocampal-dependent memory
and learning deficits, as well as MA-associated neurochemical changes. To evaluate cognitive
behavior we used the radial arm maze (RAM), which is a hippocampal-dependent task 83-84 used
to assess both long-term reference and short-term working memories 1.

Following behavioral assessments, we quantified changes in (1) dopamine-related markers
involving tyrosine hydroxylase (TH), dopamine transporter (DAT), and the Dopamine 1 receptor
(D1R); (2) glutamate receptor alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)
GluA2 subunit; (3) atypical protein kinase C iota/lambda (PKCι/λ), protein kinase Mzeta
(PKMζ) and the post-synaptic density 95 (PSD-95) protein; and (4) markers of inflammation
involving astrogliosis measured by GFAP, cycloxygenase-2 (COX-2), and prostaglandins (PG)
E2, D2 and J2. We focused on these molecular markers since MA selectively damages DA
terminals and produces excitotoxicity effects involving AMPA receptors 85-86 in addition to
elevated levels of inflammation 38. Astrogliosis is associated with MA neurotoxicity and several
other toxic insults in the brain 87. Finally, as a synaptic plasticity and memory marker, we
focused on the atypical kinase PKMζ that is important for spatial learning and long-term memory
88-89,

and which is increased concomitantly with improved memory 90 across several memory

paradigms [reviewed in 91].

Our results show that 28d on VOMA produces significant deficits in hippocampal-dependent
short-term working and long-term reference learning on the RAM. These behavioral deficits
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were associated with decreases in PKMζ, GluA2 and PSD-95. VOMA also produced decreases
in DAT and TH, with a concomitant increase in D1R levels. Both GFAP and COX-2 increased,
with decreases in PGE2 and PGD2. Thus, these results highlight the accumulating negative
effects of chronic VOMA in addition to its usefulness in characterizing the progression of the
MA-induced neurotoxicity.

2.3 Material and Methods

2.3.1

Mice

Male C57BL/6 mice from Taconic Farms (Germantown, NY) were purchased at 8 weeks of age.
Mice were randomly assigned to 2 treatment conditions: MA (n = 5) and Control (n = 5). We
have used similar sample sizes to evaluate behavioral performance and protein expression as
previously reported 1, 90, 92. Mice were housed individually to control for social effects of group
housing 93 that could affect the voluntary consumption of methamphetamine in our model. Mice
were kept on a 12/12 h light/dark cycle at the Hunter College animal facility for one week prior
to beginning any behavioral assessments with food and water ad libitum prior to behavioral
shaping. All housing conditions conform to the Hunter College guidelines outlined by the
Institutional Animal Care and Use Committee (IACUC).

2.3.2

Methamphetamine Treatment
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We used a new voluntary oral methamphetamine administration (VOMA) model over 28
consecutive days (experimental days 5-32). A sweetened oatmeal flake (Maypo, Homestat Farm,
Dublin, OH) was moistened with 8-10 μl of either MA (2.5 mg/ml) or water. This produces a
palatable sweetened oatmeal flake that contains 1mg MA/kg of body weight (bw) per serving
(adjusted to mice ranging in weight between 20-25 g). During MA administration, all mice were
transferred to individual mouse cages that were lined with absorbent paper. Each cage was
designated to a specific mouse throughout the experiment to ensure context specificity. Cages
were wiped clean and lined with fresh paper after each use. All mice remained in their paperlined cage for 30 min prior to treatment. During a 3 hour (hr) period, from 13:00 h to 16:00 h,
mice were presented with individual MA or water moistened oatmeal flakes. A new presentation
was delivered in a clean petri dish every 15 min. For each mouse, the number of consumed
flakes during the 3 hr period was noted. Directly after VOMA, all mice were fed 4g of mouse
chow daily at 18:00 h. This feeding schedule ensured that mice would be willing to consume
oatmeal flakes during the VOMA treatment time-window, for 28 consecutive days. This feeding
schedule also circumvented the significant circadian effects reported on VOMA administration
94,

without disrupting weight gain throughout the duration of the experiment.

2.3.3

Radial 8-arm Maze Shaping

The radial 8-arm maze (RAM) was used to assess both working memory and spatial learning
performance. The maze consists of a center platform (15.24 cm diameter) with 8 equivalently
sized arms radiating outward. Each arm is 38 cm in length, 6.35 cm wide and has a submerged
food cup (2.0 cm diameter) at the end of each arm. Maypo was mixed in water to make a wet
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mash used as a food reward (0.02 g portions), as previously described for mice 1 and rats 88. Prior
to working memory assessments, all animals were shaped on the RAM during days 1-2 of the
study. Mice were food restricted to 85% of free feeding weight before being placed on the RAM
for 10 min to acclimate to the maze and room cues. 1 hr later, all mice were given a second trial
with sweetened oatmeal in the food cups. After 1 day of shaping (2 trials per day), mice were
eating the food rewards and finding all 8 baits within a 15 min maximum latency.

2.3.4

Working Memory Assessment

The working memory assessment (WMA) occurred during experimental day 37. Mice were
tested for 1 day (3 consecutive trials). Each trial started with all food cups baited. To begin each
trial, mice were confined for 30 s to the center platform with a plastic cylinder. Between trials
mice were confined to the center platform while the arms were re-baited and the maze cleaned.
The sequence of arms entered to retrieve the food rewards was recorded. Mice were allowed to
collect baits from up to 3 sequential arms in any direction around the radial arm maze. Under
rare instances when a mouse adopted a chaining strategy by entering consecutive arms in one
direction around the maze, the 4th sequential arm was blocked to disrupt this non-spatial strategy
1.

Errors were recorded as re-entries into arms where the food reward had already been collected.

Working memory was assessed by a % correct score for each trial, which was calculated by the
number of total arm entries required to collect all 8 food rewards divided by 8 (the total number
of rewards collected). All mice remained on the maze until all 8 baits were collected. Maximum
latency for each trial was set at 15 min.
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2.3.5

Spatial Learning/Cognitive Flexibility Assessment

During experimental days 40-49, all mice were trained on a reference and working memory
version of the RAM as previously reported 1. This paradigm had 4 baited and 4 un-baited arms in
a pattern that was specific to each animal and remained constant throughout the experiment.
Mice were given 6 consecutive trials per day for 10 days (60 trials total). Between trials mice
were confined to the center platform while the arms were re-baited and the maze cleaned. The
sequence of arm entries was recorded. A reference memory error reflected an entry into an arm
that was never baited, while working memory errors reflected re-entries into an arm where the
bait had already been collected. Mice were only allowed to enter up to 3 sequential arms to
prevent the non-hippocampal dependent chaining strategy. This version of the RAM required
mice to learn room cues associated with the baited and un-baited arm sequence. The training
room and room cues were identical to that used for the WMA. 24 hrs after the last RAM trial, all
mice were given one reminder trial on the maze 1 hr prior to tissue retrieval. Hippocampi from
each mouse were removed, snap frozen and stored at −80oC until processed further.

2.3.6

Preparation of Tissue Fractions

Hippocampi were micro dissected and fractionated into cytosolic and synaptic fractions as
previously reported 1. Briefly, tissues were thawed and homogenized in a TEE (Tris 50mM;
EDTA 1mM; EGTA 1mM) buffer containing a Sigma Fast, protease inhibitor cocktail (Sigma
Aldrich) diluted to contain AEBSF (2 mM), Phosphoramidon (1 mM), Bestatin (130 mM), E-64
(14 mM), Leupeptin (1 mM), Aprotinin (0.2 mM), and PepstatinA (10 mM). Tissues were

21

homogenized in 200 μl of the TEE-homogenization buffer using 20 pumps with a motorized
pestle. Homogenates were transferred to Eppendorf tubes and centrifuged at 3000 x g (5 min at
4° C), to remove un-homogenized tissue. The resulting supernatant was centrifuged at 100,000 g
for 30 min. After ultracentrifugation, the supernatant was collected and stored as the cytosolic
fraction. The remaining pellet was re-suspended in 100 μl of homogenizing TEE buffer
containing 0.001% Triton X-100, incubated on ice for 1 hr and then centrifuged at 100,000 g for
1 hr at 4°C. The resulting supernatant was stored at the plasma-membrane fraction. The resulting
pellet was re-suspended in 50 μl of TEE buffer and stored as the synaptic fraction 95. The Pierce
bicinchoninic acid assay (BCA; Thermo Scientific, Rockford, IL, USA) was used to determine
protein concentration for each sample. Samples were reduced with 4x Laemmli sample buffer
equivalent to 25% of the total volume of the sample and then boiled and stored frozen at -80°C.

2.3.7

Immunoblots

Samples (20 μg) were loaded on to a Tris/Glycine 4–20% mini gel to resolve GAPDH (37 kDa),
α-Tubulin (55 kDa), PKMζ (55 kDa), PKCι/λ (68 kDa), GluA2 (102 kDa), PSD-95 (95 kDa),
COX-2 (72 kDa), GFAP (53 kDa), TH (60 kDa), D1 (49 kDa) and DAT (69 kDa). Every gel
contained 4 lanes loaded with the same control sample designated as all brain sample (ABS).
ABS was used to standardize protein signals between gels. Gels were transferred to
nitrocellulose membranes in the IBlot® Dry Blotting System (Life Technologies; Carlsbad, CA,
USA) for 7 min. Nitrocellulose membranes were then incubated in blocking solution containing
5% sucrose in Tris Buffered Saline with Tween-20 (TBST; 0.1% Tween-20 in TBS) for 30 min
at room temperature. Samples were incubated overnight with the following primary antibodies:
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GluA2 (1:2000; Chemicon, Temecula, CA, USA), PKMζ/ PKCι/λ (1:2000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), GAPDH (1:2000; Abcam Inc., Cambridge, MA, USA),
PSD-95 (1:1000; Cell Signaling Technology, Danvers, MA, USA), COX-2 (1:1000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), GFAP (1:5000; Abcam Inc., Cambridge, MA, USA), TH
(1:2000; ab152, Millipore, Billerica, MA, USA), D1 (1:2000; Abcam Inc., Cambridge, MA,
USA), DAT (1:1000; EMD Millipore, Temecula, CA, USA) and α-Tubulin (1:2000;
Calbiochem, San Diego, CA, USA). Membranes were washed in TBST for 20 min and probed
with Horseradish Peroxidase (HRP) conjugated secondary antibodies: Goat Anti-Mouse IgG (H
+ L)-HRP Conjugate #1706516 (BioRad); Goat Anti-Rabbit IgG (H + L)-HRP Conjugate
#1706515 (BioRad); Rabbit Anti-Goat IgG H&L (HRP) (ab6741-Abcam). Membranes were
incubated with Enhanced Chemiluminescence (ECL) substrate and exposed on CL-X Posure
Film (Thermo Scientific; Rockford, IL, USA). Films were scanned, and then densitometry was
performed with NIH ImageJ 96.

2.3.8

Preparation of Samples for Prostaglandin Quantification

For prostaglandin quantification, pre-weighed hippocampal tissues were homogenized in 0.9 ml
of phosphate buffered saline using a BeadBug microtube homogenizer. Following
homogenization, a 10-mg wet weight equivalent of homogenate was removed and diluted to a
final volume of 10 mg per 0.9 ml before being further diluted 1:1 with 1% formic acid.
Deuterated internal standards were added (identified in italics in the table below) to the diluted
homogenate and loaded on a 2 ml Biotage SLE+ cartridge. After a 5 min incubation, the
cartridges were eluted twice with 6 ml of t-butlymethylether. The eluent was spiked with 20 μl of
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a trap solution consisting of 10% glycerol in methanol with 0.01mg/ml butylated
hydroxytoluene. The samples were dried for 45 minutes in a speed vacuum at 35°C, the walls of
the tubes were washed with 1 ml of hexane and re-dried until a small aqueous residue remained.
The residue was dissolved in 50 μl of 80:20 water:acetonitrile with 0.1 mg/ml butylated
hydroxytoluene and spin filtered with a 0.22μm Millipore Ultrafree ® filter. Samples were
transferred to vials and 30 μl of sample were analyzed. Prostaglandin standard curves were
spiked into PBS and prepared identically to the samples. Area ratios were plotted and unknowns
determined using the slopes.

2.3.9

LC-MS/MS for Prostaglandin Quantification

Samples were analyzed using a 5500 Q-TRAP hybrid/triple quadrupole linear ion trap mass
spectrometer (Applied Biosystems, Carlsbad, CA) with electrospray ionization (ESI) in negative
mode. The mass spectrometer was interfaced to a Shimadzu (Columbia, MD) SIL-20AC XR
auto-sampler followed by 2 LC-20AD XR LC pumps. The scheduled MRM transitions were
monitored within a 1.5 min time-window (supplemental Table 1). Optimal instrument parameters
were determined by direct infusion of each analyte. The gradient mobile phase was delivered at a
flow rate of 0.5 ml/min, and consisted of two solvents, 0.05% acetic acid in water and
acetonitrile. The analytes were resolved on a Betabasic-C18 (100x2 mm, 3 µm) column at 40°C
using the Shimadzu column oven. Data was acquired using Analyst 1.5.1 and analyzed using
Multiquant 3.0.1(AB Sciex, Ontario, Canada).

2.3.10 Statistics
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For behavioral analyses, a repeated measure Two-Way ANOVA was used (Prism GraphPad 7.0a
Statistical Package, La Jolla, California). Post-hoc analyses used Bonferroni-corrected t-tests.
Western blot and PG mass-spec analyses between MA and control treatments used independent
t-tests. To characterize the generalizability of our results and support the magnitude of effects in
our studies independent of sample size, effect sizes are reported. Effect sizes were calculated as
generalized eta squared (2G) for behavioral data and Hedge’s unbiased g (g) for post-hoc
analyses and molecular data, using IBM SPSS Statistics for Mac (Armonk, NY: IBM Corp.), and
Microsoft Excel as previously described 97. For our studies, benchmark coefficient thresholds
for large effects 97 were taken into account and inflated in order to restrict significance. The
thresholds for large effect sizes in our studies were as follows: when 2G was 0.2 or higher, and
when g was 0.8 or higher. Effect sizes below these criteria were deemed moderate.

2.4 Results

2.4.1

Shaping and Methamphetamine administration

The study began with shaping animals for a total of 2 days. After 4 total days of acclimation,
subjects were randomly assigned to either a water/control group or MA for 28 consecutive days
(days 5-32). The WMA was performed on day 37 after 5 days of forced abstinence from MA.
This was followed by 10 days of cognitive flexibility assessment on the reference/working
memory version of the RAM (days 40-49). Tissue was collected on day 50 (Figure 2A). Over the
28d period mice consumed an average of 5.23 mg/kg of MA/day. Figure 2B reflects the average
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weekly consumption of MA. Control mice ate every presentation of water-Maypo. Figure 2C
shows the average weekly weights for both conditions. A two-way ANOVA shows no significant
difference between the groups [F(1,32) = 1.55, p > 0.05; 2G = 0.023, non-significant effect size]
indicating that the Maypo consumption, with or without MA, was not influenced by differences
in body weight between conditions.
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Figure 2. Timeline for the 50d study, Average Methamphetamine (MA) Consumption and
Body Weights. (A) Days 1-2: behavioral shaping on RAM. Days 5-32: VOMA for 28d. Day 37:
working memory assessment. Days 40-49: cognitive flexibility assessment (spatial learning).
Day 50: RAM test and tissue harvest. (B) The total amount of MA consumed over the 28 day
VOMA period, grouped into 4-week averages for Control and Methamphetamine (Meth) groups.
(C) Mice were weighed during the consumption period of VOMA. No significant differences
were found between the two groups when analyzed by two-way ANOVA [F(1,32) = 1.55, p >
0.05; 2G = 0.023, non-significant effect size]
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2.4.2

Radial- Arm-Maze Working and Reference Memory Assessments

Figure 3A shows the % correct scores in two separate analyses to illustrate the differences in
number of errors committed during a trial. Collecting the first 4 baits, when the working memory
load is low, shows a much higher % correct score compared to when the working memory load is
high, collecting baits 5-8. An overall 2-way ANOVA reflecting treatment condition (MA or
saline) and baits (1-4 or 5-8) shows a significant effect of bait [F (1,8) = 50.67, p < 0.001; 2G
=0.76, significant effect size]. The Bonferonni post-hoc analysis shows significant within-group
differences in both control (Bonferonni corrected t-test=3.14, p < 0.05; g= 1.57) and VOMA
(Bonferonni corrected t-test=6.93, p<0.001; g= 4.85) mice when comparing group performances
between collecting baits 1-4 and baits 5-8. Between groups, there were no significant differences
between treatments for baits 1-4 (Bonferonni corrected t-test = 0.39, p > 0.05; g= 0.23) In
contrast, VOMA produced a significant increase in working memory errors while collecting baits
5-8 compared to controls (Bonferroni corrected t- test= 3.41, p < 0.01; g= 1.92). Figure 3B
shows the latency to complete the working memory trials. There were no significant differences
between treatment conditions for latency to complete working memory trials (Figure 3B).
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Figure 3: VOMA impairs spatial working memory. (A) Two-way Repeated ANOVA showed
an overall effect of bait group (*** p<0.001). Post hoc analyses reveal that both control and MA
mice performed significantly worse to retrieve baits 5-8 compared to baits 1-4 (# indicates
different from control bait 1-4, p<0.05; ! indicates different from MA bait 1-4, p<0.001). Baits 58 reveal a significant difference between groups (^ indicates different from control in same
condition p < 0.01). (B) There was no significant difference in latency to complete the trial
between the groups.
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Figure 4 shows the behavioral analyses for RAM acquisition across 10 training days (experiment
days 40-49 shown on graphs). An overall 2-way ANOVA for % correct scores (Figure 4A)
shows a significant interaction effect of treatment on training days [F(9,72) =5.12, p < 0.01; 2G =
0.29] and time [F(9,72) =33.38 , p < 0.01; ; 2G = 0.73]. Post hoc tests show significant differences
between treatment conditions for training day 8 (Bonferroni corrected t-test = 3.45, p < 0.01; g=
1.97) and training day 9 (Bonferroni corrected t-test = 4.28, p < 0.01; g= 2.44). To determine
whether there are significant differences in asymptotic performance level between groups, we
assessed % correct scores during training days 6-10 (experiment days 45-49). This analysis
shows an overall effect of drug treatment [F(1,8) = 10.99, p < 0.05; 2G = 0.40], reflecting
differences in the level of peak performance. As predicted with asymptotic performance, there
was no significant effect of training days. Consistent with % correct score analyses, reference
memory errors shown in Figure 4B reflect an overall significant interaction effect of treatment on
training days [F(9,72) = 3.75, p < 0.01; 2G =0.25], and a significant effect of training days [F (9,72)
=25.00, p< 0.01; 2G = 0.69]. During asymptotic performance (training days 6-10 experiment
days 45-49), reference memory errors show an overall significant effect of treatment [F(1,8) =
13.8, p< 0.01; 2G = 0.33]. Analysis of working memory errors (Figure 4C) shows an overall
significant effect on training [F(9,72) = 5.25, p < 0.01; 2G = 0.35], but no significant effect
between treatment conditions. During asymptotic performance (training days 6-10, experiment
days 45-49), there was a significant effect of treatment [F(1, 8) = 5.513, p<0.05; 2G = 0.20] for
working memory errors. Together the data in Figure 4A-C demonstrate that MA is significantly
impairing the level of peak performance across multiple analyses on this spatial learning task.
Analysis of latency to complete the training trials shows a significant interaction effect of
treatment on training days [F(9,72)=4.92, p <0.01; 2G = 0.23] and an overall significant decrease
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over training days [F(9,72) = 22.01, p < 0.01; 2G =0.57]. Post-hoc tests show a significant
difference between treatment conditions on training day 1 (Bonferroni corrected t-test= 3.31,
p<0.05; g= 1.89).
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Figure 4. VOMA impairs spatial learning. All statistical analyses involved two-way ANOVA
across 10 consecutive training days (experiment days 40-49 shown on graphs) and treatment
conditions. Differences between treatment conditions during asymptotic performance (training
days 6-10, experiment days 45-49) were analyzed separately. (A) % Correct shows a significant
effect of training days (^ p < 0.0001) and treatment conditions (# p < 0.0001). Bonferronicorrected post hoc analyses revealed significant differences between treatment conditions on
training days 8 and 9, (experiment days 47-48) (** p < 0.01; *** p<0.001). During asymptotic
performance (training days 6-10) there is a significant treatment effect (! p<0.05). (B) Reference
memory errors show a significant effect on training days (^ p < 0.01), a significant interaction (#
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p < 0.01), and a significant treatment effect during asymptotic performance (training days 6-10, !
p<0.01). (C) Working memory errors show a significant effect of training days (^ p < 0.01),
without a significant difference between treatment conditions except during asymptotic
performance (training days 6-10, ! p<.05). (D) Latency to complete the trials show a significant
effect of training days (^ p < 0.01), and a significant interaction between treatment conditions (#
p < 0.01). Bonferroni post-hoc tests show a significant difference between treatment conditions
on training day 1 (p<0.05).
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2.4.3

Hippocampal Dopaminergic Marker Expression

Western blot analyses for dopaminergic markers showed a significant decrease in cytosolic TH
(t7= 2.67, p<0.05, g= 1.59; Figure 5A). In the synaptic fraction, there was a significant increase
in D1R expression (t8= 3.16, p<0.01, g= 1.81, Figure 5B) and a decrease in synaptic DAT
expression (t7= 2.16, p<0.05, g= 1.29, Figure 5C).
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Figure 5. Chronic VOMA affects dopaminergic marker expression. Compared to controls,
VOMA decreases cytosolic TH (*p<0.05; A). In the synaptic fraction, D1R significantly
increased (**p<0.01; B) and DAT significantly decreased (*p<0.05; C) compared to controls.
Representative blots show control (left band) and MA (right band) treatments. See
supplementary figures for original images of blots.
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2.4.4

Hippocampal Inflammatory Marker Expression

Inflammatory markers showed a significant increase of synaptic COX-2 (t8= 1.93, p<0.05,
g=1.09, Figure 6A) and cytosolic COX-2 (t7= 2.03, p<0.05, g= 1.211, Figure 6B). Cytosolic
GFAP was also significantly elevated compared to controls (t7= 3.86, p<0.01, g=-2.30, Figure
6C). GFAP and COX-2 increases suggest a raise in proinflammatory activity in the
hippocampus. MA-induced excitotoxicity can mediate increases of GFAP to allow for astrocyte
activation in response to MA-induced damage 98. COX-2 is an inducible inflammatory activator
that can signal other pathways, including prostaglandin synthesis, which can be protective or
toxic to neurons 99. Figure 6D-F shows analyses of PGE2, D2 and J2 in picograms per milligram
of wet weight of tissue, indicating that PGD2 levels in control mice are at least 10-fold higher
than PGE2 and PGJ2. Both PGE2 and PGD2 significantly decrease (33% and 40% respectively)
with VOMA compared to controls (t8 = 3.95, p < 0.05; g= 2.26, Figure 6D. t8=3.73, p< 0.01; g=
2.13, Figure 6E.). PGJ2, which is a PGD2 metabolite, did not change significantly between
treatment conditions (Figure 6F).
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Figure 6. Chronic VOMA increases neuroinflammation marker expression. In the synaptic
(A) and cytosolic (B) fractions COX-2 levels significantly increased compared to controls
(*p<0.05). (C) Cytosolic GFAP increased compared to controls (**p<0.01). See supplementary
figures for original images of blots. (D,E). PGE2 and PGD2 significantly decreased with VOMA
compared to controls (*p< 0.05; picograms/milligram). (F). PGJ2 expression did not change
significantly between treatment conditions. Representative blots show control (left band) and
MA (right band) treatments.
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2.4.5

Hippocampal Synaptic Plasticity Marker Expression

Compared to controls, VOMA produced a significant decline in glutamatergic and synaptic
plasticity markers including GluA2 (t6= 8.53, p<0.01, g= 5.24, Figure 7A), synaptic PSD-95 (t8=
3.38, p<0.01, g= 1.93, Figure 7B) and cytosolic PKMζ (t8=2.55, *p<0.05, g= 1.46, Figure 7C).
Cytosolic PKCι/λ expression was not altered by VOMA treatment (Figure 7D).
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Figure 7. Chronic VOMA decreases memory associated marker expression. (A) In the
synaptic fraction, VOMA decreased GluA2 (**p<0.01) and PSD-95 compared to controls
(**p<0.01; B). (C) In the cytosolic fraction, VOMA decreased PKMζ compared to controls
(*p<0.05). (D) VOMA did not significantly affect cytosolic PKCι/λ expression. Representative
blots show control (left band) and MA (right band) treatments. See supplementary figures for
original images of blots.
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2.5 Discussion

2.5.1

VOMA as a model for studying MA addiction

VOMA is a new model for assessing both the chronic and acute effects of MA. MA mixed in a
palatable sweetened oatmeal mash provides a paradigm that does not require surgery or
conditioning. This model permits the animal unrestricted movement that allows the experimenter
to test various behavioral learning paradigms. Our results demonstrate that chronic voluntary
consumption of MA results in significant spatial learning and memory deficits together with
significant changes in markers reflective of MA neurotoxicity. One of the main challenges in
MA research is designing an experiment that models aspects of human MA addiction. We find
that this VOMA model is useful for characterizing aspects of addiction, as mice are able to titer
the amount of drug administered, as reflected by a consistent level of MA consumed over several
weeks. Our results indicate that the C57BL/6 mice will voluntary consume about 1.743 mg/kg
bw/hr during a 3 hr MA administration period. These data suggest that if 5mg/kg bw MA was
delivered as a bolus dose to a mouse of this strain, even such a seemingly low dose is
considerably higher than would be consumed voluntarily. Whether there is a difference between
an injection of 5 mg/kg bw compared to voluntarily consuming this amount over a 3 hr period
remains to be determined. Other MA models have used appetitive paradigms 94 or drinking
paradigms 100 that also demonstrate the short-term behavioral and neurochemical changes
associated with small doses of voluntary MA consumption. In our current study, we examine the
behavioral and neurochemical effects of chronic voluntary MA as a way to more accurately
model human MA addiction.
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Throughout 28 days of VOMA, consumption rates increase over the first 2 weeks and stabilize
during the last 2 weeks. Previous self-administration models may only reveal a trend to increase
consumption due to the brief (2 weeks or less) administration window. It is unclear how other
self-administration models would compare to VOMA across longer periods administration (4
weeks or more). Moreover, it is important to consider how oral administration via a sweetened
medium might affect VOMA. Control mice in our study consumed every presentation of waterMaypo (12 baits/day over 28 days), revealing a preference for sweetened food by this mouse
line. However, mice that consumed water-Maypo laced with MA consumed less than half of the
baits presented to them each day on average (see Results). This reveals that although a sugar
preference could motivate consumption of the MA-baits, mice rapidly adapt a strategy to
consume only as much MA-Maypo as they prefer. Mice on VOMA could still develop a
preference to MA as a result of the sweetened medium, but more work is needed to determine
this. Future studies should examine how the drug’s medium affects consumption rates across
long periods of MA access.

The use of an oral administration design is validated by previous work indicating that the mean
half-elimination life of oral MA is not significantly different from that of the intravenous route,
and that peak plasma concentration is delayed via the oral route by 3 hrs in humans, compared to
other routes 101-102. This suggests that VOMA can model the delayed effects of MA on the brain,
and very adequately reveal the prolonged neurotoxic effects of the drug. Additionally, previous
work has revealed that although the injection route may be preferred by a subset of highlyaddicted individuals, non-injection routes make up a high percentage of MA use in the United
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States 103. Nonetheless, our study models oral MA administration, a route not likely preferred by
MA-addicted humans. Non-injection MA administration might be preferred by individuals who
have not yet developed an addiction. In order to fully understand the distinct populations that
abuse MA, more research is needed to clarify the onset and progression of this addiction in
humans as it relates to administration routes. Future VOMA studies should examine the
progression and relapse of MA consumption in VOMA in order to accurately characterize the
addictive phenotype produced by our model.

2.5.2

MA-induces deficits in both spatial working and reference memory performance

Our results show that total MA consumption of 146.4 mg/kg bw/28 consecutive days result in a
significant spatial working memory performance deficit. Our previous study reports working
memory deficits following neurotoxic doses of MA (30 mg/kg bw delivered once per week for 2
weeks; 60mg/kg bw total). These working memory deficits developed over a 4 week abstinence
period 1. The working memory deficit observed in our current study may have developed much
earlier based on the levels of MA consumed. However, reports by others suggest that lower
doses of MA delivered chronically may have less harmful or delayed cognitive effects, compared
to bolus or neurotoxic doses 38, 104. The latter studies are consistent with the protective effects
observed when escalating doses of MA are delivered over days that show reduced cognitive and
neurochemical deficits, compared to neurotoxic effects and the resulting cognitive deficits that
result from a bolus dose 105-108. Rapid deficits in working memory performance identified 24 hrs
following a neurotoxic dose of MA were previously reported 38. However, without repeated
assessments over time, it is difficult to determine whether the working memory deficits are long
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lasting or are reflective of the short-interval between MA treatment and working memory testing.
It is possible that shortly after MA administration, mice are low on seeking novelty, an effect that
is rectified weeks after MA treatment as demonstrated in rat performance on the spontaneous
alternation task 109.

Following the working memory assessment, mice were tested for cognitive flexibility on the
RAM. For this assessment, both working and reference memory errors were scored. The MA
treated mice exhibited a lower asymptotic performance level for % correct scores and an increase
in the number of reference and working memory errors compared to mice given control
treatment. This is consistent with several other studies reporting spatial memory deficits
following a short abstinence period 110-112. Others have shown that chronic use of MA can
actually stave off MA-induced deficits, which can then be initiated following long-periods of
abstinence. In this case, cognitive deficits were observed only following long-term abstinence (14 weeks) 1, 104, 113-114. The degree to which VOMA produces neuroprotection and/or can delay the
neurotoxic effects of MA remains to be determined.

2.5.3

Chronic VOMA decreases TH and DAT while increasing D1R levels

Our previous studies revealed that acute neurotoxic doses of MA (2x 30 mg/kg) followed by 6
weeks of forced abstinence produce long-lasting decreases in dopamine marker expression in the
hippocampus 1. In our current study, we found that VOMA for 28d also produced significant
decreases in these markers in the hippocampus. Previous work has shown that within days of
injecting neurotoxic doses of MA, the striatum exhibits a comparable decrease in DA levels 115-

43

120.

MA-induced reductions of TH and DAT in the striatum may indicate degeneration of DA

axonal terminals 121-124. This explanation is supported by increased reactive astrogliosis
associated with MA treatment 122, 125-126. We hypothesize that decreased DAT and TH together
with an increase in astrogliosis reflects a degeneration of DA terminals within the hippocampus.
Whether our VOMA paradigm produces similar effects in the striatum remains to be determined.

VOMA also induced a significant increase in D1R expression. This receptor is known to mediate
some of the MA-driven neurotoxic effects in the striatum 127 and PFC 128. Selective D1R
antagonists delivered prior to injections of binge doses of MA produce neuroprotective effects
against the MA-induced decreases in DA, TH and DAT 118. Moreover, increases in MA-induced
extracellular DA causes acute increases in striatal glutamate as a result of D1R mediated
disinhibition of corticostriatal glutamate release 129. Together these findings suggest that
increased D1R expression is detrimental and/or exacerbates the neurotoxic damage from MA. In
contrast, it has been suggested that D1R activation is a neuroprotective response. Dopamine
suppresses glutamatergic hippocampal and entorhinal neurotransmission by activation of the
D1R 130. Additionally, D1R activation can reduce NMDA receptor mediated Ca2+ currents in
hippocampal neurons, thus decreasing excitotoxicity 131. The D1R also plays a role in reducing
calcium currents in striatal neurons 127, and in producing inhibition on N-type voltage-gated
calcium channels 132. Therefore, it is possible that alterations in other receptor levels dictate
whether increased D1R-levels are beneficial or detrimental. Future studies will evaluate the
changes in NMDA and mGluA receptor subunits, which could add to understanding the
consequences of these neurochemical changes. For example, antagonism of NMDA, AMPA or
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metabotropic (mGluR5) receptors can block MA-induced toxicity in the striatum 133-135 or
hippocampus 136.

2.5.4

Neuroinflammatory marker levels increase in the hippocampus following chronic VOMA

We show that compared to controls, GFAP and COX-2 protein levels are elevated in the
hippocampus after 28d of VOMA. We propose that these changes in inflammatory markers
reflect a neurodegenerative response to MA. COX catalyzes the conversion of arachidonic acid
to prostaglandins (PG) and thromboxanes. COX-1 is constitutively expressed, whereas COX-2 is
induced upon stimulation by various proinflammatory agents (endotoxins, cytotoxins) 99, 137.
Elevated levels of COX-2 in the hippocampus increase the extracellular concentration of
glutamate, exacerbating glutamate-associated excitotoxicity 138-141. Our results are consistent
with what is observed following neurotoxic doses of MA 142. Conversely, COX-2 KO mice are
resistant to MA-dependent dopamine depletion in the striatum that results from high doses 143,
suggesting that COX-2 up-regulation exacerbates the neurotoxic effects of MA 144-145. Other
reports show temporary GFAP increases in the hippocampus 24h after neurotoxic doses of MA,
which return to basal levels by 7d post injection 39, 142. These data suggest that the rapid increases
in GFAP induced by a neurotoxic dose of MA may reflect activation of a neuroregenerative
response, as this marker is expressed during neurogenesis in the subgranular zone of the dentate
gyrus 146. Based on these findings, it is possible that the accumulating (low doses) of MA during
VOMA prolong the short-term increase in GFAP that has been observed following neurotoxic
doses. Future studies should characterize the time course for the onset and progression of GFAP
expression in the hippocampus after VOMA.
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Following a regimen of neurotoxic MA administration (4× 10 mg/kg, 2 h apart, i.p.), mice
exhibit cytotoxic brain edema driven by increases in hippocampal and striatal aquaporin-4
channels on astrocytes 147. Increased GFAP expression in the hippocampus following VOMA
suggests that after chronic MA abuse, the hippocampus is vulnerable to breakdown of the bloodbrain barrier resulting in cytotoxic edema. Astrocytes are one part of the complex neurovascular
niche and aquaporins play a pivotal role in regulating water and cerebro-spinal fluid (CSF) flow
into and out of the neuronal space 148-149. It is unclear how and when this dysregulation in
aquaporin-mediated shifts in water/CSF emerges and is resolved after chronic MA abuse. Future
studies should examine the role that aquaporin-mediated cytotoxic edema plays in VOMAinduced neural and cognitive deficits.

PGE2 and PGD2 levels decrease following VOMA. PGD2 is the most abundant of the PGs in
the brain followed by PGE2, and both PGs induce secretion of nerve growth factor and brainderived neurotropic factor 150. In addition, both PGD2 and PGE2 were found to have
neuroprotective effects in the CNS 151-153. These studies suggest that decreased levels of PGD2
and PGE2, together with increased expression of COX-2 could mediate a neurotoxic response to
VOMA. It is possible that the decrease in PGE2 reflects an increase in the 15hydroxyprostaglandin dehydrogenase (15-PGDH), a key enzyme in the metabolism of PGE2. An
ALS mouse model shows that 15-PGDH increases throughout the progression of the disease
specifically in GFAP positive astrocytes, while PGE2 only increased at the end stage of the
disease 154. No other studies have measured PGs in the hippocampus following MA. One study
examined binge doses of MA on PGE2 in the striatum showing no changes in PGE2 levels up to
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48 hrs following MA 143. Further work is needed to delineate how these different MA models
affect PGs across various brain regions.

PGJ2 is a product of spontaneous dehydration of PGD2, which is the most abundant
prostaglandin in the brain 155 and the one that changes the most under pathological conditions156.
PGJ2 is a highly neurotoxic prostaglandin 157, as it impairs both the ubiquitin-proteasome
pathway 158-159 and mitochondrial function 160. This PG also up-regulates COX-2 161, most likely
leading to a positive feedback loop between itself and COX-2 99. In supplementary studies, we
have observed that PGJ2 levels increase following 6 weeks of abstinence after acute neurotoxic
doses of MA (2x 30 mg/kg; supplementary Figure 1) and also increases following 4 weeks of
abstinence after a 2 week VOMA period (25 mg/kg total MA consumed over 14d; supplementary
Figure 2). However, mice given 28d of VOMA did not exhibit increases in PGJ2 (Figure 6F).
These data suggest that abstinence may be playing a role in the increased expression of PGJ2.
This finding is consistent with previous studies indicating that abstinence from MA can
exacerbate memory deficits 1, 114.

Our results suggest that the duration of abstinence and of MA-administration could play
opposing roles in promoting or suppressing PGJ2 levels in the hippocampus. We hypothesize
that a long period of abstinence from MA promotes PGJ2 expression, but that a longer period of
MA administration mitigates it through increased dopamine release. This hypothesis is consistent
with the understanding that dopamine is anti-inflammatory by inhibiting the activation of NODlike receptor containing Pyrin domain-3 (NLRP3) inflammasome by D1R activation 162.
Additional studies have shown that low doses of MA, which increase dopamine release, are
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neuroprotective following oxygen-glucose deprivation 163. However, it remains to be determined
how abstinence from MA contributes to increases in PGJ2.

2.5.5

MA decreases synaptic memory markers

Our results show that the levels of PKMζ and AMPA receptor subunit GluA2 decrease following
VOMA. PKMζ is important for both late-phase LTP 164 and long-term memory maintenance
across various learning paradigms 88, 91, 165-166. It is also important to note that increased GluA2
synaptic expression is important for spatial memory 90, 167, as is the trafficking of AMPA
receptors by PKMζ 168-169. These studies are consistent with the decline in PKMζ and GluA2
levels following VOMA. We also assessed the protein levels of PKCι/λ, another atypical kinase
known to support spatial memory in the conditional-PKMζ KO mouse 170, suggesting that
PKCι/λ is active when PKMζ is compromised. PKCι/λ expression was not significantly altered
following VOMA, suggesting that deficits in PKMζ may not reflect neurotoxic damage, but
rather reflect poor learning.

GluA2 is one of the four AMPA receptor subunits impermeable to Ca2+ and is the dominant
heteromeric conformation 171-172. Reduced GluA2 levels were shown to increase neurotoxicity in
amyotrophic lateral sclerosis motor neurons 173-174. We hypothesize that decreased GluA2 and
PKMζ mediate spatial learning impairment as well as the elevated neurotoxic effects of MA.
This is consistent with chronic MA treatment. In contrast, studies by others examining acute
doses of neurotoxic MA report increased levels of GluA2 shortly after treatment 38, suggesting
that elevated hippocampal GluA2 levels may be contributing to a neuroprotective response by

48

MA. However, after several weeks of abstinence, hippocampal GluA2 levels return to baseline 1.
Together these results suggest that early after MA, hippocampal GluA2 increases as a
neuroprotective mechanism, while following chronic MA a decline in hippocampal GluA2 could
exacerbate MA neurotoxicity. These results are also consistent with our behavioral data,
indicating that GluA2 decline in the hippocampus could underlie the spatial memory deficits
found in VOMA mice.

Our results also show a significant decrease in PSD-95 protein levels. PSD-95 is primarily
located in the neuronal spine head and its density reflects synaptic efficacy 175. Moreover,
increases in PSD-95 spine density are associated with improved memory performance 176-178.
These findings are consistent with the poor memory performance and reduced hippocampal
PSD-95 level in the MA treated mice. PSD-95 levels also increase in the forebrain following
MA-induced place preference 179, suggesting PSD-95 involvement in memory rather than a
secondary effect of MA-induced toxicity.

2.6 Conclusions

Our data demonstrate that chronic VOMA leads to significant deficits in spatial learning and
short-term working memory, which is consistent with reports by others. Additionally, our results
show that low doses of MA consumed over a 3 hr period can produce significant neurotoxic
changes in the hippocampus, reproducing the neurochemical effects observed in studies using
bolus or neurotoxic doses of MA. Chronic VOMA also leads to significant decreases in TH and
DAT and an increase in D1R expression as seen with neurotoxic and binge doses of MA. These
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neurochemical changes are accompanied by increases in both COX-2 and GFAP that were
previously reported. In concert with the decline in PGE2 and PGD2 levels, these data may reflect
extensive neurotoxic damage attributed to MA. Finally, decreases in synaptic markers relevant to
spatial long-term memory involving both GluA2 and PKMζ are consistent with neurotoxicityinduced deficits in working memory and spatial learning. The time course for the onset and
progression of these various neurochemical changes in the VOMA model remains to be
determined. These data are consistent with what is observed in MA addicts showing low levels
of dopamine, DAT and TH associated with cognitive impairment 34, 180. Together these studies
support the significance of this VOMA mouse model in identifying risk factors and exploring
potential remediation therapies against MA addiction.
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2.7.Supplementary Figures

Figure 8. Supplemental Figure 1. Prostaglandin levels in hippocampus after 14d VOMA
followed by 4wks of abstinence. (A) PGE2 and (B) PGD2 levels did not differ between
treatment conditions. (C) PGJ2 levels significantly increased in MA condition compared to
controls (t9=2.23; *p=0.026, g=1.34)

Figure 9. Supplemental Figure 2. Prostaglandin J2 levels increase in mice hippocampi 6
weeks after two bolus doses of MA (2x 30 mg/kg). (A) PGE2 and (B) PGD2 levels did not
differ between treatment conditions. (C) PGJ2 levels significantly increased in MA 6-week
condition compared to MA 3-day condition (t5=3.24; *p=0.023, g= 2.09)
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Table 2: MRM transitions for prostanoids and deuterated internal standards for PG Mass
Spectrometry. The scheduled MRM transition values monitored within a 1.5 min window.

ID

Q1

Q3

RT

DP

PGD2

351.1

233

6.20

-60

-10

-18

-19

d9 PGD2

360.1

280.2

6.15

-55

-10

-26

-19

PGE2

351.0

189.1

5.9

-85

-10

-26

-5

PGJ2

333

233.2

7.59

-55

-10

-16

-9

d9 PGE2

360.2

280.2

5.9

-75

-10

-28

-11

6 keto PGF1α

369.1

163.1

4.2

-120

-10

-38

-3

d4 6 keto PGF1α

373.1

167.2

4.2

-120

-10

-38

-11

IsoP VI

353.2

115.0

5.5

-55

-10

-30

-5

8,12 IsoP VI

353.1

115.0

6.6

-85

-10

-30

-7

d4 IsoP VI

357.2

115.0

5.5

-125

-10

-30

-9

IsoP III

353.2

193.0

5.2

-105

-10

-36

-3

IsoP IV

353.0

126.9

5.0

-75

-10

-32

-11

d4-IsoP III

357.2

197.0

5.2

-125

-10

-36

-7

PGF2α

353.1

193

5.7

-55

-10

-34

-31

d4 PGF2α

357.1

197

5.7

-55

-10

-34

-31

TXB2

369.1

169.1

5.2

-75

-10

-28

-5

11 dehydroTXB

367.1

305.2

6.0

-65

-10

-24

-11

d4 TXB2

373.1

173.1

5.2

-60

-10

-30

-5
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CHAPTER 3: TWO-WEEKS OF VOLUNTARY ORAL METHAMPHETAMINE
ADMINISTRATION PRODUCES ACUTE SPATIAL-MEMORY DEFICIT AND
INCREASES NEUROINFLAMMATION DURING ABSTINENCE
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3.1 Abstract
Methamphetamine (MA) is a neurotoxic drug of abuse. It can produce neurodegenerative
processes in the brain that impair behavioral and cognitive functions. The mechanisms that
underlie MA-induced neurodegeneration are well characterized, but less is known about how
MA induces behavioral and cognitive deficits. Furthermore, little is known about the progression
of behavioral deficits immediately after MA abuse and during abstinence. To address these gaps
in knowledge, our lab has developed a voluntary oral administration model of MA (VOMA)
using mice. Male C57Bl6 mice were put through VOMA for 14 days followed by a prolonged
period of abstinence. During VOMA, mice were allowed to voluntarily consume up to 16mg/kg
of MA each day. During and after VOMA, mice were put through a battery of cognitive and
behavioral assessments to test drug sensitization, spatial memory capacities, and long-term
retention. Our results show that VOMA produces subsets of MA consumers in mice, accurately
modeling voluntary MA abuse in humans. Our behavioral data reveals that VOMA produced an
acute sensitization to MA, and an acute working spatial memory deficit directly after VOMA.
However, VOMA did not produce a long-term spatial learning or retention deficit during
abstinence. Hippocampal tissue analyses of mice from different timepoints reveal that abstinence
significantly increases neuroinflammation, and significantly contributes to modulations in
synaptic dopamine transporter and 5-5-hydroxytryptamine receptor 2A (5HT2a) expression. Our
study characterizes the progression of behavioral changes that follow MA administration,
revealing that mice do not exhibit cognitive deficits during abstinence. Neurochemical analyses
reveal that abstinence contributes to major changes in hippocampal neuroinflammation and
monoamine protein expression. These findings provide new insight into the complex behavioral
resilience and neurochemical susceptibility exhibited by MA subjects during abstinence.
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3.2 Introduction
Methamphetamine (MA) is a highly neurotoxic and addictive psychostimulant. Studies show that
MA is increasing in popularity and abuse in the United States181. MA exposure during critical
developmental periods can impair cognition in rodents182, as well as humans183, and can
significantly affect neurochemistry184. Chronic MA users develop hallucinations29 as well as
cognitive deficits in attention, memory, information processing, and impulse control25-28. MA
abuse can also trigger negative emotional states such as depression during drug withdrawal and
abstinence185. These deficits may be attributed to neurodegeneration of the frontal cortex,
midbrain and hippocampus35. Additionally, increased MA exposure correlates with greater
locomotion in mice186-187 and can also affect various unconscious physiological behaviors such
as food intake188. In order to determine the progression of behavioral changes following MA
intake, the current study used a new model of methamphetamine administration labeled
Voluntary Oral Methamphetamine Administration (VOMA)189. Previous MA administration
animal models have used binge and neurotoxic dosing via injections 45. These models do not
accurately represent the human model since people are not likely to take binge or neurotoxic
doses in a short periods of time. Instead, humans may opt to spread out similar MA doses over a
longer span of time. The VOMA model allows mice to titer the amount of MA they consume in a
day and over many weeks. For this particular study, we exposed mice to VOMA for 2 weeks and
a long abstinence period of up to 7 weeks prior to tissue collection or behavioral assessments.

The trajectories in behavioral and neurochemical changes during abstinence from MA remain
unclear. MA abuse can produce long-term cognitive impairments in abstinent individuals3-5. It
has also been shown that long periods of abstinence from MA can improve the recovery of
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decision making-skills and emotional symptoms6 which may help individuals to avert relapse.
Yet, other reports indicate that relapse can still occur after prolonged abstinence7, as a result of
exposure to specific environmental cues8. The underlying neurochemical pathways that result in
relapse during abstinence remain unclear. Previous work has implicated glutamatergic signaling
in the nucleus accumbens as pivotal in addiction models190, and recent evidence has also linked
hippocampal neurogenesis to context-dependent MA memory during abstinence191-192. A
thorough understanding of the neurochemical mechanisms underlying MA relapse during
abstinence would provide pharmacological targets to assure successful recovery from addiction.
Since the abstinence and relapse are also vital to studying addiction193, our experiments focused
on tissue analyses from two (2) timepoints following VOMA, to characterize the progression of
neurochemical changes in this animal model of drug abuse.

As a result of MA-induced neurotoxicity, neuroinflammatory pathways are activated in the brain
involving astrocytes and pro-inflammatory enzymes57, 145, 194. The contribution of abstinence to
neuroinflammatory pathway activation and/or silencing is unclear. Parallel neurochemical
changes following MA abuse include those that also occur in psychiatric disorders, including
changes to dopamine and serotonin signaling195-196. Previous literature has revealed a link
between serotonin signaling, via the 5HT2a receptor, with cognition197, hallucinogenic drugs198199

and psychiatric disorders200. Additionally, MA abusers also show decreased density of

dopamine transporters (DAT) in the striatum and frontal cortex33, 46-47, as markers for
degeneration of DA innervations in the brain121-124. It is unclear when DAT function is
compromised following MA exposure and under what circumstances this function is restored
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during abstinence. Our study characterizes changes in these markers following VOMA and after
abstinence.

3.3 Methods
3.3.1

Animals

All experimental conditions, housing, and drug administration procedures were reviewed and
approved by the Institutional Animal Care and Use Committee (IACUC) of Hunter College. Two
(2) cohorts of male C57Bl6 mice (N=71 total; cohort 1 n=22, cohort 2 n=49) purchased from
Taconic Biosciences were used for this study. Upon purchase, animals were received at Hunter
College’s Animal facility aged 6 weeks. Mice were individually housed, kept on a 12h/12h
light/dark cycle from 7:30h to 19:30h, and fed standard rodent chow ad libitum for 1 week prior
to handling and starting baseline assessments. Mice were housed individually to control for
social effects of group housing 93 that could affect the voluntary consumption of
methamphetamine in our model.

3.3.2

Food restriction

In order motivate mice to consume MA baits, strict food-restriction schedules were instituted for
both MA and control mice. Standard rodent chow was delivered at 18:00h, at a ratio of 1g of
chow per 5g of body weight, every day for the duration of the study. This feeding schedule
ensured that mice would be willing to consume MA-oat baits during the VOMA administration
window each day without disrupting weight gain or loss during the experiment, as previous work
has reported significant circadian effects in a similar VOMA administration design 94.
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3.3.3

VOMA

From two (2) cohorts of mice, n=17 mice were placed into control treatment and n=54 mice were
placed into VOMA. Daily body weights were recorded, and 1 or more dosing solutions were
formulated for each weight class, restricted to within 5 grams of body-weight variability.
Working MA dosing solutions of 0.8 to 0.9 mg/mL (in water) was made and prepared for
administration. Mice were housed in standard polycarbonate cages for drug administration
procedures. Each cage was used for the same mouse throughout the experiment to minimize
housing stressors. Methamphetamine (0.007 mL at 1mg/kg and ~0.8mg/mL) was dissolved into
oatmeal bran chips (Maypo Inc.) and served 16 times per day to each mouse, at 15-minute
intervals. Control mice received water absorbed by oat chips. Experimenters administered
individual MA-oatmeal chips to each mouse and tracked consumption before delivering new
MA-oat baits. Administration room was kept isolated from surrounding noise and activity.
VOMA and control administration was carried out between 12:00h and 18:00h every day for the
duration of the experiment.

3.3.4

Sensitization-induced mobility in test cage

A subset of mice (n=12 control, n=13 low consumers and n=9 high consumers) were used for
tests of sensitization measures. Mice were analyzed for mobility in their VOMA cage to measure
sensitization prior to receiving MA. Mobility was defined as time mice spent running, jumping,
walking, interacting with nests, and climbing on the bars of the cage. Three-minute videos were
recorded of each subject. Mobility of each subject determines degree of sensitization and
anticipation of MA delivery on day 8 (after one week of VOMA) and day 15 (one day after the
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VOMA period). Mice did not receive MA on day 15, but rather were only exposed to their MA
cage to capture videos and then promptly returned to their home cage.

3.3.5

Radial Arm Maze Shaping and Baseline Working Memory Assessments

The radial 8-arm maze (RAM) was used to assess both working memory and spatial learning.
The maze consists of a center platform (15.24 cm diameter) with 8 equivalently sized arms
radiating outward. Each arm is 38 cm in length, 6.35 cm wide with a submerged food cup (2.0
cm diameter) at the end of each arm. Ensure was used as a food reward (0.007mL per bait).
Prior to the start of VOMA, all animals were shaped on the RAM. Mice were food restricted to
~85% of free feeding weight. On day 1 of RAM shaping, mice were placed on the RAM for
5min to acclimate to the maze and room cues, with food baits available around maze and inside
food cups. On day 2 of shaping, mice were given 15min each to explore the maze and the food
baits on ends of maze-arms and inside cups. On day 3 baseline working memory performance
was recorded. Mice were given 15min each to collect small baits at the ends of arms.
Performance on days 3 was used to balance groups across treatments.

3.3.6

Radial Arm Maze Working Memory Assessment

Working memory assessment (WMA) was assessed 2 days after end of VOMA and 4 weeks into
abstinence, for a subset of mice not slated for tissue collection (n=11 control, n=13 low
consumers and n=8 high consumers). One (1) trial was used to assess performance at each time
point. Before starting each trial, all food cups were baited with Ensure. To begin a trial, mice
were confined for 30s to the center platform with a plastic cylinder. The sequence of arms
entered to retrieve the food rewards was recorded. To prevent a non-spatial strategy, mice were
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allowed to collect baits from up to 3 sequential arms (in any one direction around the radial
maze) before the experimenter interrupted the chaining strategy. Errors were recorded as reentries into arms where the food reward has already been collected. Maximum latency for each
trial was set at 15min.

3.3.7

Radial Arm Maze Spatial Learning / Cognitive Flexibility Assessment

28d after VOMA, a subset of mice (n=6 control, n=5 low consumers and n=6 high consumers)
were trained on a reference memory version of the RAM as previously reported1. This paradigm
has 4 baited and 4 un-baited arms in a pattern specific to each animal and remained constant
throughout the experiments. Mice were given 6 consecutive trials per day for 10 days (60 trials
total). Between trials mice were confined to the center platform while the arms were re-baited,
and the maze cleaned. The sequence of arm entries was recorded. A reference memory error
reflects an entry into an arm that was never baited, while working memory errors reflect reentries into an arm where the bait had already been collected. Mice were only be allowed to enter
up to 3 sequential arms (in any one direction around the radial maze) to prevent the nonhippocampus dependent chaining strategy. This version of the RAM requires mice to learn room
cues associated with the baited and un-baited arm sequence. The training room and room cues
were the same to those used for the WMA.

3.3.8

Radial Arm Maze Retention Memory test

The Retention Memory test used the same parameters and arm sequences used during the
cognitive flexibility/reference memory assessment. Three (3) trials using the same baited
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sequences from the learning assessment were used to test the memory performance of each
mouse that underwent the reference learning paradigm.

3.3.9

Tissue Collection

Following the end of VOMA and 4 weeks days of abstinence, designated mice underwent
controlled cervical dislocation of the skull from the spine and brain tissue was harvested.
Hippocampi from each mouse were microdissected, snap frozen and stored at −80 oC until
processed further.

3.3.10 Fractionation
Following tissue collection, a subset of mice tissues from each consumption group were used for
western blotting analyses (n=5 control, n=2 low-abstinence consumers, n=4 low+abstinence
consumers, n=3 high-abstinence and n=5 high+abstinence consumers). Collected tissue was
fractionated into cytosolic and synaptic fractions as previously reported189. Briefly, tissues were
thawed and homogenized in a TEE (Tris 50mM; EDTA 1mM; EGTA 1mM) buffer containing
Sigma Fast, a protease inhibitor cocktail (Sigma Aldrich) diluted to contain AEBSF (2 mM),
Phosphoramidon (1 mM), Bestatin (130 mM), E-64 (14 mM), Leupeptin (1 mM), Aprotinin (0.2
mM), and PepstatinA (10 mM). Tissues were homogenized in 200μl of TEE-homogenization
buffer using 20 pumps with a motorized pestle. Homogenates were transferred to Eppendorf
tubes and centrifuged at 3000 x g (5 min at 4° C), to remove un-homogenized tissue. The
resulting supernatant was centrifuged at 100,000 g for 30 min. After ultracentrifugation, the
supernatant was collected and stored as the cytosolic fraction. The remaining pellet was resuspended in 100μl of homogenizing TEE buffer containing 0.001% Triton X-100, incubated on
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ice for 1hr and then centrifuged at 100,000 g for 1hr at 4°C. The resulting supernatant was stored
at the plasma-membrane fraction. The resulting pellet was re-suspended in 50 μl of TEE buffer
and stored as the synaptic fraction95. The Pierce bicinchoninic acid assay (BCA; Thermo
Scientific, Rockford, IL, USA) was used to determine protein concentration for each sample.
Samples were reduced with 4x Laemmli sample buffer equivalent to 25% of the total volume of
the sample and then boiled and stored frozen at -80°C.

3.3.11 Western Blotting Analysis
Hippocampi were collected form mice directly following VOMA and after 4 weeks of abstinence
(mice from each consumer groups were allocated to –Abstinence and +Abstinence sub-groups,
balanced for MA consumption). The tissue was separated into synaptic fractions as previously
reported1. Samples (20 μg) were loaded on to a Tris/Glycine 4–20% mini gel to resolve: GFAP
(55 kDa), GAPDH (37 kDa), DAT (69 kDa), COX-2 (72 kDa), 5-HT2a (53 kDa.). Every gel
contained 3-4 lanes loaded with the same control sample designated as all brain sample (ABS).
ABS was used to standardize protein signals between gels. Gels were transferred to
nitrocellulose membranes in the IBlot® Dry Blotting System (Life Technologies; Carlsbad, CA,
USA) for 7 min. Nitrocellulose membranes were then incubated in blocking solution containing
5% sucrose in Tris Buffered Saline with Tween-20 (TBST; 0.1% Tween-20 in TBS) for 30 min
at room temperature. Samples were incubated overnight with the following primary antibodies:
GFAP (1:2000; Abcam Inc., Cambridge, MA, USA), GAPDH (1:2000; Abcam Inc., Cambridge,
MA, USA), DAT (1:2000; EMD Millipore, Temecula, CA, USA), COX-2 (1:2000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and 5-HT2a (1:2000; EMD Millipore, Temecula, CA,
USA). Membranes were washed in TBST for 20 min and probed with Horseradish Peroxidase
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(HRP) conjugated secondary antibodies: Goat Anti-Mouse IgG (H + L)-HRP Conjugate
#1706516 (BioRad); Goat Anti-Rabbit IgG (H + L)-HRP Conjugate #1706515 (BioRad); Rabbit
Anti-Goat IgG H&L (HRP) (ab6741-Abcam). Membranes were incubated with Enhanced
Chemiluminescence (ECL) substrate and exposed on CL-X Posure Film (Thermo Scientific;
Rockford, IL, USA). Films were scanned, and then densitometry was performed with NIH
ImageJ 96.

3.3.12 Statistics
For behavioral analyses, a repeated measure t-test, a repeated measures ANOVA and two-way
ANOVA was used. Post-hoc analyses used a Bonferroni-corrected t-test. For data-sets that
included missing values due to tissue collection attrition designs, a Type III Mixed Effects model
analysis design was used. Molecular analyses used a One-way ANOVA and Bonferroni
corrected post-hoc comparisons. Prism GraphPad 7.0 (La Jolla, California) was used for all
statistical analyses.

3.4 Results
3.4.1

VOMA models naturalistic MA consumption

The experiment was conducted over 10 weeks, with VOMA running for 14d during study weeks
1 and 2. Behavior Assessments were carried out throughout the experiment. Tissue collection for
western blot analyses occurred after 14-day VOMA and after 4 weeks of abstinence (Fig11A).
Consumption of each subject was recorded throughout the 14-day VOMA period (Fig11B).
Tracking of consumption revealed distinct consumer classes in mice. Subjects were split into two
distinct groups for respective behavioral and neurochemical analyses: high and low consumers.
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High consumers averaged 2.36 mg/kg per day (n=34; 33.15 mg/kg total over 14d). Low
consumers averaged 1.39 mg/kg per day (n=20; 19.4 mg/kg total over 14d). Both groups’
consumption rates dropped from week 1 to week 2, suggesting a failure in producing sustained
MA preference in this experiment. A Two-way repeated measures ANOVA of MA consumption
rates between the groups revealed an effect of day (F13, 676=21.69, p<0.001) and effect of
group (F1,52=33.94, p<0.001). Post hoc comparisons revealed significant differences on days
1,2,3,4,6,7,8,9,10,11 and 12 (p>0.05). Weights of each subject was measured throughout the
whole experiment (Fig11C). A Type III mixed effects model was run to analyze body weights of
all groups throughout the experiment. A significant effect of day was observed (F9,420=121.1,
p<0.001). No significant effects between groups were observed.
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Figure 10. Experimental design, Methamphetamine consumption and Body weights. (A)
Over 10 weeks, mice were assessed for various behavioral measures, put through 14 days of
VOMA, and tissue collected (red asterisks*) at designated timepoints. (B) Consumption of each
subject was recorded throughout the 14-day VOMA period. Due to the wide range of
consumption rates, mice were split into two distinct groups: high (n=34) and low (n=20)
consumers. High consumers averaged 2.36 mg/kg per day (33.15 mg/kg total over 14d). Low
consumers averaged 1.39 mg/kg per day (19.4 mg/kg total over 14d). Both groups’ consumption
rates dropped from week 1 to week 2, suggesting a failure in producing sustained MA preference
in this experiment. (C) Weights of each subject was measured throughout the whole experiment.
No significant difference was found between each of the groups.
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3.4.2

VOMA consumers show transient sensitization

The mobility of mice in their respective drug-administration cages prior to starting any VOMA
procedures may serve as a measure of sensitization and potentially, anticipation of MA
administration. Three (3) minute videos were captured for n=12 control, n=13 low consumers
and n=9 high consumers inside their drug administration cages before the start of any VOMA
procedures. Blinded observers quantified each video for mobility of each mouse. A One-way
ANOVA of mobility at the end of week 1 revealed a significant overall effect of group
[F2,31=6.699; p<0.005]. Post hoc analyses revealed significant differences between High
consumers (**) vs. low consumers (p<0.05) and, separately, High consumers vs controls
(p<0.005) (Fig 12A). A One-way ANOVA of mobility at the end of week 2 revealed no
significant group effects (Fig 12B).
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Figure 11. VOMA-induced sensitization. VOMA-Cage mobility prior to start of VOMA
delivery indicates sensitization to MA and potentially anticipatory awareness of VOMA delivery.
(A) Week 1 mobility analysis revealed a significant overall effect of treatment. Post hoc analyses
revealed significant differences between High consumers (n=9; **) vs. low consumers (n=13;
p<0.05) and controls (n=12; p<0.005). (B) Week 2 mobility analyses revealed no significant
overall effect of treatment.
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3.4.3

VOMA produces acute spatial working-memory deficit not present during abstinence

Working memory assessments were run prior to and after VOMA. Baseline working memory
assessments were used to balance groups into either VOMA or control. A subset of mice for used
to test working memory performance over the course of the study (n=11 control, n=13 low
consumers and n=8 high consumers). Baseline performance for these mice shows no appreciable
difference between groups (Fig 13A; 2days, 1 trial per day). A Two-way ANOVA of WM
Baseline performance between control mice and Low Consumers revealed a significant effect of
bait (F1,22=158.6; p<0.001) and no significant effect of treatment. A Two-way ANOVA of WM
Baseline performance between control mice and High Consumers revealed a significant effect of
bait (F1,17=107.8; p<0.001) and no significant effect of treatment. A Two-way ANOVA of WM
Baseline performance between High Consumers and Low Consumers revealed a significant
effect of bait (F1,19=133.3; p<0.001) and no significant effect of treatment. Directly following
VOMA, 1 WM trial was run for all mice (Fig 13B). A Two-way ANOVA of WM performance
after VOMA between control mice and Low Consumers revealed a significant effect of bait
(F1,22 =82.49; p<0.001) and no significant effect of treatment. A Two-way ANOVA of WM
performance after VOMA between control mice and High Consumers revealed a significant
effect of bait (F1,17 =72.03; p<0.001) and a significant effect of treatment (F1,17 =5.096;
p<0.05). Post-hoc comparisons of performance between groups in each bait-group revealed a
marginal difference between groups on baits 5-8 (t34=2.194, p=0.07). A Two-way ANOVA of
WM performance after VOMA between High Consumers and Low Consumers revealed a
significant effect of bait (F1,19 =154.4; p<0.001) and a significant effect of treatment (F1,19
=6.176; p<0.05). Post-hoc comparisons of performance between groups in each bait-group
revealed a significant difference between groups on baits 5-8 (t38=2.46, p<0.05). Following a 4-
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week abstinence period, 1 more WM trial was run for all mice (Fig 13C). A Two-way ANOVA
of WM performance between control mice and Low Consumers revealed a significant effect of
bait (F1,22 =61.27; p<0.001) and no significant effect of treatment. A Two-way ANOVA of
WM performance between control mice and High Consumers revealed a significant effect of bait
(F1,17 =50.48; p<0.001) and no significant effect of treatment. A Two-way ANOVA of WM
performance between High Consumers and Low Consumers revealed a significant effect of bait
(F1,19 =34.69; p<0.001) and no significant effect of treatment.
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Figure 12. Working Memory Assessment. Working memory performance was tracked for a
subset of mice across the study. (A) Baseline performance is not different between treatment
groups. (B) After VOMA, 1 WM test revealed that High consumers performed significantly
worse than control and low consumers (*). (C) After 4 weeks of abstinence, WM performance
was no different between treatment groups.
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3.4.4

Abstinence does not affect RAM spatial learning

A subset of mice (n=6 control, n=5 low consumers and n=6 high consumers) were chosen to
undergo further cognitive testing on the RAM. Mice underwent spatial-reference memory
training over a 10d period (Fig 14A). A Two-way ANOVA of learning performance between
control mice and Low Consumers revealed a significant effect of day (F9,81=12.96, p<0.001)
but no significant effect of treatment. A Two-way ANOVA of learning performance between
control mice and High Consumers revealed a significant effect of day (F9,72=12.24, p<0.001)
but no significant effect of treatment. A Two-way ANOVA of learning performance between
High Consumers and Low Consumers revealed a significant effect of day (F9,63=11.06,
p<0.001) but no significant effect of treatment. A Two-way ANOVA of reference-memory errors
between control mice and Low Consumers revealed a significant effect of day (F9,81=21.12,
p<0.001) but no significant effect of treatment (Fig 14B). A Two-way ANOVA of referencememory errors between control mice and High Consumers revealed a significant effect of day
(F9,72=14.43, p<0.001) but no significant effect of treatment. A Two-way ANOVA of
reference-memory errors between High Consumers and Low Consumers revealed a significant
effect of day (F9,63=11.08, p<0.001) but no significant effect of treatment. A Two-way ANOVA
of working memory errors control mice and Low Consumers revealed a significant effect of day
(F9,81) =3.739, p < .001), no significant effect of treatment, and a significant interaction of day
and treatment effect (F9,81=2.408, p<0.05). Post hoc comparisons found no significant
differences between groups. A Two-way ANOVA of working memory errors control mice and
High Consumers revealed a significant effect of day (F9,72) =5.888, p < .001) but no significant
effect of treatment. A Two-way ANOVA of working memory errors High Consumers and Low
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Consumers revealed a significant effect of day (F9,63) =4.236, p < .001) but no significant effect
of treatment (Fig 14C).
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Figure 13. Reference Memory Assessment. (A) Reference memory assessment shows an
overall effect of day within first five days of learning but not within the last five days of learning,
after running a Two-way ANOVA. This indicates a more drastic increase in learning in the first
five days compared to the last four. (B) All mice showed a gradual decrease in reference errors
over time that was not significant between groups. (C) Working memory errors made throughout
19d of training were not different between groups. also gradually decreased, indicating a general
improvement of memory and performance throughout the experiment.
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3.4.5

Abstinence does not affect RAM retention memory

Eight (8) days after the end of the RAM reference-training phase, mice were put back on the
maze to complete a retention test of the memory learned during the training period within 3
trials. A One-way ANOVA of the performance on the RAM revealed no significant differences
between groups (Fig 15A). A One-way ANOVA of the reference-memory errors revealed no
significant differences between group (Fig 15B). A One-way ANOVA of the working-memory
errors revealed no significant differences between groups (Fig 15C). These results highlight the
behavioral resilience and plasticity that subjects experience during abstinence.
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Figure 14. Retention Memory Test. Eight (8) days after the end of RAM training, a retention
test was run for all mice. (A) Performance on the tests was not significantly different between the
treatment groups. (B) Reference memory errors during the retention test were not significantly
different between the treatment groups. (C) Working memory errors during the retention test
were not significantly different between the treatment groups.
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3.4.6

Abstinence upregulates neuroinflammation in the hippocampus

Western blot analyses of hippocampal tissue followed. A One-way ANOVA of GFAP revealed
an overall effect of group (F4,16 =5.734; p<0.01) and controlled post hoc analyses revealed that
the high consumption group significantly decreased GFAP compared to controls (*; p<0.05) and
that abstinence in the same consumption group brought GFAP levels closer to control (Fig 16A).
A One-way ANOVA of COX-2 across groups revealed an overall effect of treatment (F4,16
=8.897; p<0.001) and controlled post hoc comparisons revealed significant differences between
control mice and the high consumption mice that underwent abstinence (*; p<0.01) (Fig 16B).
These results highlight the progression of neuroinflammation in the brain that occurs during
abstinence.
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Figure 15. Neuroinflammation increases after prolonged abstinence following VOMA. (A)
VOMA decreases GFAP levels in the hippocampus of high consumers and abstinence modulates
its levels closer to control. (B) Abstinence increases COX-2 levels significantly in high
consumers compared to other treatment groups.
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3.4.7

Abstinence decreases DAT and increases 5-HT2a in the hippocampus

A One-way ANOVA of hippocampal DAT revealed an overall effect of treatment (F4,14
=5.902; p<0.01) and post hoc analyses revealed a significant difference between control mice
and High consuming mice that underwent abstinence (**; p<0.01) (Fig 17A). A One-way
ANOVA of hippocampal 5HT2A revealed an overall effect of treatment (F4,13 =17.4; p<0.001)
and post hoc analyses revealed a significant difference between control mice and High
consuming mice that underwent abstinence (***; p<0.01) (Fig 17B). These results highlight the
progressive dysregulation of monoamine protein expression that occurs as a result of abstinence.
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Figure 16. Synaptic Monoamine proteins are modulated after prolonged abstinence. (A)
Hippocampal DAT decreases appreciably directly in high consumers after VOMA but
significantly decreases after a prolonged abstinence period. (B) Hippocampal 5HT2a does not
change following VOMA, but abstinence increases its expression significantly in high
consumers.
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3.5 Discussion
3.5.1

Acute VOMA models naturalistic MA abuse

To investigate the progression of behavioral, and neurochemical changes produced by MA and
abstinence, we used the VOMA model to put mice through 14 days of MA administration prior
to starting abstinence. High consumers averaged 2.36 mg/kg per day (33.15 mg/kg total over
14d). Low consumers averaged 1.39 mg/kg per day (19.4 mg/kg total over 14d). Additionally,
both groups’ consumption rates dropped from week 1 to week 2, suggesting that this model
produced declining MA preference. This claim is supported by our data showing different
sensitization-induced mobility across the drug administration weeks (Fig 12). The distribution of
Low and High MA consumers in this study confirms our hypothesis that VOMA can model
naturalistic MA abuse. Recent studies have begun to delineate the genetic risks associated with
MA preference201-202. However, we cannot discount environmental factors within our study
design affecting MA preference. Pavlovian conditioning studies in humans have shown that
extinction procedures can quickly decrease preference for MA203, while the number of drug
presentation only modestly increase drug-induced responding204. Thus, more work is needed to
understand the variables that produce various rates of drug consumption within VOMA.

3.5.2

Behavioral changes following MA abuse

Our behavioral analyses following VOMA revealed that High consuming mice exhibited an acute
spatial working-memory deficit directly after the drug administration period but not during
abstinence. This suggests that the cognitive deficits induced by 14 days of VOMA are only
transient and further, that the adolescent mouse brain has sufficient plasticity to overcome this
deficit. This claim is strengthened with the data from the spatial learning paradigm where MA
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mice showed no reference memory or retention deficits during a prolonged abstinence period (Fig
14). Future studies should compare the long-term cognitive effects of this VOMA design on adult
vs adolescent mice. Previous studies have shown that MA administration can produce cognitive
deficits after 1 or 3 weeks of abstinence following 16mg/kg MA administered over an 8hr period104,
113

and throughout 3 weeks of abstinence following 14 days of 24mg/kg MA administration per

day (but not directly after MA administration)114. Additionally, a comparative study examining the
effects of 13 days of escalating doses of MA on single-day binge MA (up to 16mg/kg MA) vs a
single-day binge alone showed that the addition of escalating MA doses over multiple days
prevented cognitive deficits produced by binge MA after 1 week of abstinence74. A previous
experiment from our lab observed cognitive deficits following MA administration after 7 weeks
of abstinence following 2x 30mg/kg MA doses (but not before)1, Thus, it seems that MA can
negatively affect cognition depending on the MA administration design and the timing of
assessments following MA administration. 14 days of VOMA may prove insufficient to produce
any robust cognitive deficits within the timeline of the present study, as the administration design
spreads out doses over many hours per day, over 2 weeks, similar to previous studies using
escalating MA doses74, 205. Nevertheless, having observed neurochemical changes after 4 weeks of
abstinence in the present study, the cognitive deficits could have developed shortly after the tissue
was collected. Future studies should characterize the cognitive performance of mice under this
model at later timepoints, comparable to those of previous studies1.

3.5.3

DAT as a clinical marker of interest for MA abuse and abstinence

Our current study shows that VOMA decreases DAT in High consumers that received abstinence.
High consumers that received no abstinence before tissue collection showed decreased DAT levels
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but not to the extent of abstinent mice. These results indicate that abstinence plays a major role in
the reduction of DAT levels following VOMA. Our previous studies showed that acute neurotoxic
doses of MA (2x 30 mg/kg) followed by 6 weeks of forced abstinence produce long-lasting
decreases in dopamine marker expression in the hippocampus 1. Previous studies of DAT
availability in the brains of human MA users show recovery of DAT levels206 as well as sustained
decreases in levels207 during abstinence. Reduction in dopamine terminals and transporters are
known to be an increased risk-factor for Parkinson’s Disease

33-34,

suggesting that VOMA can

model neurodegenerative changes in the brain. Decreases in DAT levels can indicate decreases in
DA terminal function and density in the brain208. We hypothesize that decreased DA availability
following MA abuse can lead to activation of compensatory mechanisms , such as increased
5HT2a-depepdent DA release209. Previous studies indicate that 5HT2a crosstalk with DA
pathways can affect synaptic plasticity, learning and memory210-211. However, the role of 5HT2a
upregulation during abstinence following VOMA is unclear and should be explored in future
research. Additionally, MA can increase astrocytosis via DAT-dependent neurotoxicity, as mice
lacking the transporter do not show increased GFAP mRNA or immunostaining 116. In the present
study, GFAP levels are decreased after VOMA and return to control levels after abstinence (Fig
16), suggesting that astrocyte-dependent neurotoxicity was attenuated in these mice. Previous
research shows that GFAP levels increase following MA exposure, within a week after a bolus
30mg/kg MA dose126 and following a 5-day, 3x daily binge of 5mg/kg MA 212, with concomitant
decreases in DAT levels. VOMA may produce a delayed and longer-lasting shift in astrocyte
activity that could polarize glial signaling to the neurotrophic/A2 end of the spectrum 213-214,
resulting in partial neuroprotection of DA terminals in the long-term. Future research should
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characterize the effects of A1 and A2 astrocyte signaling on DAT levels and DA terminal health
following MA exposure.

3.5.4

5HT2a signaling in MA abuse

Our study also reveals that abstinence increases 5HT2a levels in the hippocampus. In the context
of drug addiction, 5HT2a is known to play a major role in the development of cocaine
sensitization215-216, and chronic MA upregulates 5HT2a in the medial prefrontal cortex, perirhinal
cortex, and dorsal hippocampus217-218, brain regions pivotal to executive function and memory.
Current studies on the potential of 5HT2a as a pharmacological target within studies of MA
abuse are inconclusive217, 219-220, but previous work has shown that this receptor underlies the
reinforcing properties of MDMA221. In The 5HT2a receptor is also known to play roles in
learning and memory (see review222) as well as aberrant cognitive processes as seen in
psychiatric disorders200. Whereas presynaptic 5HT2a may regulate neurotransmitter release209,
post-synaptic localization may underlie pivotal molecular signaling needed to promote learning
and memory222, such as diaglycerol-IP3 and ERK pathways. The 5HT2a-dependent signaling
that follows chronic MA abuse has not been explored. However, the increased levels of 5HT2a
observed during a long-term abstinence in the current study suggest that the changes on this
receptor may underlie the behavioral performance observed on the RAM tasks. The result also
suggests that these mice may have developed a latent re-sensitization during abstinence as a
result of the increased 5HT2a. Future studies should characterize the changes in this receptor in
addiction-related brain regions, such as the NAc, PFC and others. Additionally, several lines of
evidence have linked auto-receptor, 5HT1b, function to MA addiction223-225. We hypothesize
that in the context of chronic voluntary MA abuse, 5HT2a-dependent drug sensitization is
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modulated in direct response to 5HT1b auto-receptor activity. This idea is consistent with
preliminary, unpublished data from 5HT1b KO VOMA studies showing that female KO mice
consume less MA over 28 days compared to male KO mice (Appendix I). This result suggests
that 5HT1b KO mice have a loss of auto-receptor function in the brain that may require less MA
to produce euphoric effects and/or that these mice must adopt increased self-regulation due to
aversive effects of MA abuse. Future studies should examine the effects of VOMA on 5HT2a
expression in these mice across sexes.

3.5.5

Chronic neuroinflammatory pathways in the context of MA

Analyses of COX-2, the inducible pro-inflammatory enzyme responsible for downstream
inflammatory activity226, revealed that High consumers that received 4-weeks of abstinence
showed significantly increased levels compared to controls. Non-abstinent mice showed
comparably lower COX-2 levels compared to controls. Unpublished data from studies using bolus
(60mg/kg total) MA have revealed that 7 weeks of abstinence upregulates COX-2 and ubiquitin
expression in the hippocampus (Appendix II). These data suggest that inflammation might be
exacerbated during long periods of abstinence, despite not showing differences shortly after MA
exposure. MA-induced neurotoxicity can activate microglia early on after MA abuse227, that can
induce inflammatory molecular signaling detrimental to neuronal function (reviewed in45). Acute
neuroinflammation is essential to neuronal survival, but repetitive activation of neuroinflammatory
responses may contribute to neurodegenerative processes, as seen in many neurodegenerative
disease models228-229. Pro-inflammatory pathways include cyclooxygenases, specifically COX-2
which produces neurotoxicity after MA abuse73. COX-2 upregulation can form a chronic
inflammatory feedback loop with prostaglandin J2 (PGJ2)161. PGJ2 is a highly neurotoxic
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prostaglandin

157,

as it impairs both the ubiquitin-proteasome pathway

158-159

and mitochondrial

function 160, leading to aggregation of ubiquitinated proteins and failure of protein turnover. This
mechanism provides one pathway that neuroinflammation can transition from acute to chronic
states230. Previous work using our VOMA model investigated the changes in prostaglandin levels
in mice hippocampi. Mass spectrometry analyses revealed that a cohort of male C57 mice that
consumed an average total of 25.8 mg/kg MA over 14 days of VOMA showed increased PGJ2
levels in the hippocampus after 4-weeks of abstinence189. In the same study, mice that were
injected with 60 mg/kg MA over 2 weeks also showed increased PGJ2 levels in the hippocampus
after a prolonged abstinence period. Previous studies have shown that chronic unpredictable stress
and MA can interact to significantly increase COX-2 in the cerebral vasculature within 1 week of
abstinence231. Recent evidence indicates that microglial and COX-2 play major roles in
dopaminergic neurotoxicity 1 week after an ethanol and MA challenge232. Our current study
reveals that even low doses of VOMA over 2 weeks can produce a delayed increase in COX-2,
observed 4 weeks into abstinence. This delayed neuroinflammatory response may reflect a latent
susceptibility to MA-induced changes. Future studies should investigate the effects that increased
COX-2 may have on parallel immune pathways such astrocyte activity, which is known to
participate in crosstalk with the primary proinflammatory mediators, microglia233.

3.5.6

Neuroglial activity following MA abuse

Finally, analyses of GFAP expression, a marker of astrocyte activation234, revealed that VOMA
significantly decreases its levels and that abstinence brings its expression comparably closer to
baseline levels (Fig 16). MA-induced reductions of DAT may indicate degeneration of DA axonal
terminals 121-124. This explanation is supported by increased activation of astrocytes associated with
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MA treatment

122, 125-126.

Increases in GFAP have been observed at 24h post neurotoxic MA

administration and decrease 7 days after injection235. Increases in GFAP may indicate a
regenerative response in the brain146, and suggests that this neuroinflammatory response works to
regenerate MA-induced neurochemical deficits. Previous work on MA-induced effects on
neuroglia have found that acute MA can induce a polarized neurochemical activation in microglia
to M1, or proinflammatory, while decreasing their M2, or neurotrophic, activity236 Similarly, two
types of astrocyte populations have been reported during neuroinflammation: A1 astrocytes are
pro-inflammatory and neurotoxic237 and A2 astrocytes secrete neurotrophic factors to promote
neuroprotection213. Previous work in brain injury models indicate that various pathways could
promote neuroprotective activity by astrocytes238-240. Future research should elucidate the
expression of A1 and A2 astrocyte populations following VOMA and abstinence.

3.6 Conclusion and Clinical Implications
Our study characterizes a time-course of behavioral and molecular deficits that occur following
voluntary oral administration of methamphetamine. Our VOMA study provides evidence that
low doses of voluntary MA do not produce long-lasting behavioral deficits. Neurochemical
analyses showed that VOMA produced only a significant decrease in GFAP levels. Tissue
collected after 1 month of abstinence revealed more changes in monoamine protein and
neuroinflammatory marker expression. These results suggest that despite receiving low doses of
MA, VOMA can model long-lasting neurochemical changes that may reflect susceptibilities to
neurodegenerative processes present during abstinence. Our data provide new avenues of
research to investigate the neurochemical changes that ensue during abstinence periods, and its
effects on behavior and cognition in-vivo.
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4.1 Abstract
Studies show that females exhibit increased susceptibilities to psycho-stimulant addiction
compared to males. Additionally, adolescence may contribute to female-specific vulnerabilities
to addiction. However, little is known about the underlying mechanisms in the brain that produce
this vulnerability in adolescent female populations. To model methamphetamine addiction, we
used a mouse model for voluntary oral methamphetamine administration, (VOMA). Previous
work suggests VOMA can model voluntary consumption that mirrors human binge patterns over
28 consecutive days, unlike other models that utilize bolus doses over shorter periods of time.
Additionally, our current study used an escalating-dose regimen over the first 10d to maximize
the administration rate over the remaining 18d of VOMA. Over the course of 28d, we found that
male mice consumed an average 4.67 mg/kg/day over 28d and female mice consumed an
average 5.84 mg/kg/day over 28d. In order to evaluate differential neurotoxic effects of MA
between sexes, we focus on medium consumers of MA whose consumption rates across both
sexes were not significantly different: male mice consuming an average 7.68 mg/kg/day over 28d
and female mice consuming an average 8.2 mg/kg/day over 28d. Following VOMA, behavioral
assessments revealed that VOMA did not alter depression in the tail suspension task but
decreased anxiety in both sexes on the elevated plus maze (EPM). VOMA females, but not
males, showed increased exploratory behavior on the EPM. In a hippocampal dependent
working memory task (radial arm maze), adolescent female, but not male, VOMA mice show
working memory deficits. The sex-specific behavioral changes occurred while both sexes
voluntarily consumed equivalent amounts of MA. The behavioral results occur in tandem with
sex-specific neurochemical changes in the hippocampus, specifically involving glycogen
synthase kinase-3 beta (GSK3β)-associated molecular activity. Male, but not female, adolescent
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mice exhibit neuroprotective molecular changes in response to VOMA including increases in
dopamine receptor 1 (D1), estrogen receptor alpha (ERα) phosphorylated Akt (pAkt), and
pGSK3β/GSK3β ratio. Further, females show an increase in D-prostanoid receptor 1 (DP1)
levels and a concomitant increase in kappa opioid receptor (OR) in the nucleus accumbens
(NAc) suggesting a response to increased neuroinflammation that males do not exhibit. These
results suggest that an escalation MA administration protocol may potentiate the sex-differences
in neurochemical resilience observed in male, but not female adolescent mice. The results further
indicate that female mice show molecular deficits in the brain compared to males. Our study
reveals that female mice show specific susceptibilities to methamphetamine challenges and offer
potential molecular mechanisms for this phenomenon.
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4.2 Introduction
Methamphetamine is a highly addictive psychostimulant, showing higher rates in adolescent
females compared to adult female lifetime users 241. Clinical reports indicate that females begin
using MA recreationally at a younger age, and transition more quickly to MA addiction that
leads to intravenous use compared to males 242. Female MA users also reported greater severity
of drug use and psychological burden than males 243, including increased rates of depression,
psychosis, and suicide 244-246. In males, but not females, drug craving was correlated with
depression and anxiety 247. Recent reports show females have sustained vulnerability to the
neurotoxic effects of MA following prolonged abstinence, showing greater reductions in
hippocampal volumes and wide-spread reduction in grey matter compared to control females,
whereas no difference was observed between METH-abusing and control male subjects 248-249.

Rodent studies have also identified sex-differences in MA self-administration 250 251. Female rats
show accelerated MA self-administration compared to males 252-254 and more rapidly reinstated
drug-seeking compared to males 253, 255. While few studies have identified signaling mechanism
associated with sex-dependent drug seeking behaviors 256-257, even fewer studies have identified
the neurochemical effects of long-term or chronic MA on adolescent male and female mice 78-80.
Therefore, the current study investigated the chronic behavioral and neurochemical
consequences of voluntary oral methamphetamine administration (VOMA) in adolescent male
and female mice.

Our study focuses on select signaling pathways and synaptic markers that are known to be
selectively affected by MA. Previous studies have identified acute and chronic deficits in
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dopamine related markers following binge and VOMA models 118, 189, 258. Thus, we examined the
effects of the dopamine transporter (DAT), the dopamine precursor tyrosine hydroxylase (TH)
and the dopamine receptor 1 and 2 (D1, D2) in hippocampus following chronic MA. The effect
of neurotoxic or binge dosing of MA shows increased susceptibility in males than females as
observed by more extensive striatal DA reduction and larger decreases in DAT 78, 259-261. These
studies suggest a role for estrogen as an underlying neuroprotective mechanism and are
consistent with the report on BALB/c mice showing greater MA-induced vulnerability in females
during diestrus (low estrogen) compared to proestrus (high estrogen) 260. Based on these
findings, we evaluated the long-term consequences of chronic VOMA on ERα and its
downstream activation of Akt and GSK3β signaling pathways. Since MA produces different
effects on dopaminergic markers in female and male mice, these findings provide important new
information related to the signaling pathway differences in toxicity induced by chronic MA
exposure. To examine potential dysphoric effects between males and females during 2 weeks of
abstinence after chronic 28d MA, we evaluated the expression of the −opioid receptor (OR)
and D1 in the NAc.

Additionally, our study focuses on the sex-differences in hippocampal molecular signaling.
Previous studies have revealed that rodents activate distinct molecular cascades across the sexes
following hippocampal-dependent spatial training 262-263. Available evidence indicates that
female spatial learning is influenced greatly by fluctuations in gonadal hormone availability
throughout the estrous cycle, with optimal performance observed during the proestrus phase 264,
and is thought to be driven by proliferative molecular signaling in the hippocampus 264. More
recently, it has been shown that female mice exhibit heightened corticosterone responses
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following MA challenges compared to males, driven by hippocampal and hypothalamic HPAaxis dependent glucocorticoid signaling 265. These findings suggest that females may be
specifically vulnerable to MA-induced cognitive deficits and neurochemical shifts.

We focus our analysis on groups of males and females that voluntarily consumed equivalent
amounts of MA. Our results show that following 28d VOMA, females show a deficit in spatial
working memory performance, but males do not. VOMA males show increased hippocampal D1
with a concomitant increase in ERα and enhanced downstream signaling including pAkt and the
pGSK3β/GSK3β ratio, but females do not. VOMA females show elevated D-prostanoid receptor
1 (DP1) and a decrease in DP2 suggesting elevated neuro inflammation. In the NAc, females
show lower levels of D1 and increased κOR in VOMA females compared to female controls.
These findings highlight the differential effects and elevated vulnerability of the adolescent
female to the neurotoxicity of chronic MA and possibly enhanced dysphoric effects during
abstinence which contribute to our understanding of the neural mechanisms that may underlie
differential vulnerabilities to MA between sexes.

4.3 Methods

4.3.1

Animals

Male (n=20) and female (n=20) C57/bl6 mice were purchased from Taconic Biosciences and
were received at Hunter College’s Animal facility at 6 weeks of age. Mice were individually
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housed, kept on a 12h/12h light/dark cycle from 7:30h to 19:30h, and fed ad libitum for 1 week
prior to handling.

4.3.2

Food restriction

At the start of their 2nd week in the facility, mice were transitioned from ad libitum food to being
fed daily rodent chow that weighed 20% of the average body weight (approx. 4g chow for males
and 3.5g chow for females per day). For RAM assessments, weights were recorded for 5d and
diets were restricted until mice reached 85% of their baseline BW. Working memory assessment
on the 8-arm Radial Maze, lasted 4d total with shaping and baseline assessments included.
Following RAM memory assessments, mice were fed daily rodent chow that weighted 20% of
the average BW. Feeding mice daily chow weighing 20% of their BW allowed for a continuous
increase in BW reflecting growth (Fig 1).

4.3.3

Radial 8-arm Maze Shaping/Baseline

The radial 8-arm maze (RAM) was used to assess spatial working memory. The maze consists of
a center platform (15.24 cm diameter) with 8 equivalently sized arms radiating outward. Each
arm is 38 cm in length, 6.35 cm wide with a submerged food cup (2.0 cm diameter) at the end of
each arm. Maypo (Homestat Farm, Dublin, OH) was mixed in water to make a wet mash that
that was used as a food reward (0.02 g portions), as previously described for mice 189 and rats 88.
On day 1 of RAM shaping, mice were placed on the RAM for 5 min to acclimate to the maze
and room cues, with food baits available around maze and inside food cups. On day 2 of shaping,
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mice were given 15 min each to explore the maze and the food baits on ends of maze-arms and
inside cups. On days 3 and 4 of shaping, mice were given 15 min each to collect small baits at
the ends of arms. Performance on days 3 and 4 was recorded and used to balance groups across
conditions based on baseline RAM performance.

4.3.4

Working Memory Assessment

After 4d of abstinence mice underwent working memory assessments (WMA). Mice were tested
over 2 days (1 trial/day). Each trial started with all food cups baited. To begin each trial, mice
were confined for 30s to the center platform with a plastic cylinder. The sequence of arms
entered to retrieve the food rewards was recorded. To prevent a non-spatial strategy, chaining,
mice were allowed to collect baits from up to 3 sequential arms before the experimenter
interrupted the chaining strategy. Working memory errors were recorded as re-entries into arms
where the food reward has already been collected. Maximum latency for each trial was set at 15
min.

4.3.5

Tail Suspension

After 5 days of abstinence, mice underwent behavioral assessments. To assess for depressive
phenotypes, we used the tail-suspension test. Mice were hung by their tails and suspended three
feet in the air. Mice were kept suspended for six minutes and videos were recorded. Video
scorers were blinded to the animals’ experimental condition. Scorers tracked and recorded the
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time spent immobile for each mouse. Immobility was considered any lack of voluntary taxis or
body movements, including the torso, limb, or head.

4.3.6

Elevated Plus Maze

After 7d of abstinence, mice were placed on the elevated plus maze (EPM) assessment. This
behavioral assay assesses anxiety and related behavioral phenotypes. Lighting conditions on and
around the EPM inside the testing room were kept consistent for all mice. Lux was maintained
high (average 200 lux on and around EPM) to measure for anxiolytic effects of chronic MA
exposure 266. Following a 15-minute acclimation to the testing room, each mouse was placed
onto the center of the EPM, facing an open arm opposite from the experimenter. The mouse was
allowed to explore the EPM for 8 minutes. Videos were recorded for each mouse. Video scorers
quantified the number of open and number of closed arm entrances for each mouse. Arm entries
were scored when all four mouse paws crossed into the 75% remaining length of an arm (from
the center to the end).

4.3.7

MA formulation

A stock solution 40mg/mL of methamphetamine hydrochloride (Sigma Aldrich) was formulated
using de-ionized water. Daily body weights were used to calculate working volumes of EnsureMA solutions for each weight class. From 40mg/mL stock, Ensure-MA solutions were delivered
to mice in 7μL containing a maximum dose of 1mg/kg bw MA.
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4.3.8

Voluntary oral methamphetamine administration

A cohort of 40 mice (n=20 per sex) were assigned into drug and control groups, balanced across
treatments with bw and baseline working memory performance. VOMA groups contained n=14
mice per sex and Control groups (no MA, Ensure only) contained n=6 mice per sex. On the 15th
day following their arrival, mice began the Escalation phase of VOMA: 3 days of 1 dose/day at
0.25 mg/kg MA per bait; 3 days of 4 doses/day at 0.25 mg/kg MA per bait; 2 days of 16
doses/day at 0.25 mg/kg MA per bait; and 2 days of 16 doses/day at 0.5 mg/kg MA per bait.
From day 11 to day 28 of VOMA, mice received 16 doses/day at 1 mg/kg MA per bait. Doses of
MA were delivered at 15 min intervals for a total period of administration lasting 4 h. Following
each bait presentation, the number of consumed bait was recorded for each animal. Control mice
had untreated Ensure delivered at the same bait/hour/day rate as MA treated mice.

4.3.9

Tissue sample collection and fractionation

Following 28d of VOMA and 15 days of abstinence where behavioral testing was done,
hippocampal and nucleus accumbens (NAc) tissue from all animals were collected on day 15 of
abstinence. Tissues were flash frozen on dry ice. To fractionate tissue into cytosolic and synaptic
fractions as previously reported 258. Briefly, tissues were thawed from frozen and homogenized
in a TEE (Tris 50 mM; EDTA 1 mM; EGTA 1 mM) buffer containing a SigmaFast, protease
inhibitor cocktail (Sigma Aldrich) diluted to contain AEBSF (2 M), Phosphoramidon (1 M),
Bestatin (130 M), E-64 (14 M), Leupeptin (1 M), Aprotinin (0.2 M), and Pepstatin A (10
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M). Tissues were homogenized in 200 l of the TEE-homogenization buffer using 20 pumps
with a motorized pestle. Homogenates were transferred to Eppendorf tubes and centrifuged at
3,000 g (5 min at 4o C), to remove unhomogenized tissue. The resulting supernatant was
centrifuged at 100,000 g for 30 min. After ultracentrifugation, the supernatant was collected and
stored as the cytosolic fraction. The remaining pellet was resuspended in 100 l of
homogenizing TEE buffer containing 0.001% Triton X-100, incubated on ice for 1h and then
centrifuged at 100,000 g for 1h at 4° C. The resulting pellet was resuspended in 50 l of TEE
buffer and stored as the synaptic fraction 95. The Pierce bicinchoninic acid assay (BCA)
(Thermo Scientific, Rockford, IL) was used to determine protein concentration for each sample.
Samples were reduced with 4x Laemmli sample buffer equivalent to 25% of the total volume of
the sample and then boiled and stored frozen at -80o C.

4.3.10 Protein quantification and western blot assessments

Samples (20 g) were loaded onto a Tris/Glycine 4-20% midi gel to resolve gapDH (36 kDa),
D1 (49 kDa), D2 (50 kDa), TH (60 kDa), DAT (69 kDa), ERα (66 kDa), Akt (56 kDa),
phosphorylated s473-AKT (60 kDa), GSK3β (46 kDa), phosphorylated s9- GSK3β (46 kDa),
PKCι/λ (68 kDa), PKM (55 kDa), COX-2 (72 kDa), DP1 (46 kDa), DP2 (~64 kDA), and κOR
(~58 kDa). Every gel contained 3-4 lanes loaded with the same control sample, (all brain
samples, ABS). ABS were used to standardize protein signals between gels. Gels were
transferred to nitrocellulose membranes in IBlot® Dry Blotting System (Life Technologies;
Carlsbad, CA) for 9 minutes. Nitrocellulose membranes were then incubated in blocking solution
containing 5% sucrose in Tris Buffered Saline with Tween-20 (TBST; 0.1% Tween-20 in TBS)
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for 30 minutes at room temperature. Samples were incubated with the following primary
antibodies for 18-36hrs: gapDH (1:2000; Abcam Inc., Cambridge, MA, USA), D1 (1:2000;
Abcam Inc., Cambridge, MA, USA), D2 (1:2000; Abcam Inc., Cambridge, MA, USA), TH
(1:2000; EMD Millipore Corp., Billerica, MA, USA), DAT (1:2000; EMD Millipore Corp.,
Billerica, MA, USA), ERα (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA), Akt (1:2000;
Cell Signaling Technology, Danvers, MA, USA), phosphorylated s473-AKT (1:2000; Cell
Signaling Technology, Danvers, MA, USA), GSK3β (1:2000; Cell Signaling Technology,
Danvers, MA, USA), phosphorylated s9- GSK3β (1:2000; Cell Signaling Technology, Danvers,
MA, USA), PKM/ PKCι/λ (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA), COX-2
(1:2000; Santa Cruz Biotechnology, Santa Cruz, CA), DP1 (1:500; Cayman Chemical, Ann
Arbor, Michigan, USA), DP2 (1:2000; ThermoFisher Scientific, Waltham, MA, USA ), and κOR
1:2000; Abcam Inc., Cambridge, MA, USA). Membranes were washed in TBST for 20 min and
probed with Horseradish Peroxidase (HRP) conjugated secondary antibody. Membranes were
incubated with Enhanced Chemiluminescence (ECL) substrate and exposed on CL-XPosure Film
(Thermo Scientific; Rockford, IL). GapDH was used as a control to standardize for protein
concentration loaded on gels. Films were scanned for quantification with NIH Image J.

4.3.11 Statistical analyses

For behavioral and molecular analyses, a 1-way ANOVA across treatment groups 2-way
ANOVA (sex x drug treatment) were used (Prism GraphPad 6.0 Statistical Package, La Jolla,
California). Post-hoc analyses used controlled comparisons Bonferroni-corrected t tests.
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4.4 Results

4.4.1

Behavioral Shaping

Analyses of RAM baseline and post-VOMA performance revealed one female mouse as an
outlier from the rest of the group (z-scores 1.6 SDs and 1.5 SDs, respectively) and thus is not
included for subsequent behavioral or molecular assays; total female control n=5. A timeline is
provided to depict the duration of and the description for each phase of in-vivo assessments, to
include RAM assessments and VOMA [Fig18A].

4.4.2

Voluntary Ensure Consumption

Across 28d of VOMA, n=6 male and n=5 female mice underwent control exposure to the
Ensure, vehicle. For the first 3 days, mice were exposed to a total of 1 Ensure bait per day. For
the next 3 days, mice were exposed to a total of 4 baits per day at 1 bait every 15min. From Day
7 onward, control mice received 16 Ensure baits per day at 1 bait every 15min. Over the course
of the 28d VOMA, control mice ate all Ensure baits. There were no differences in Ensure
consumption between control male and control female mice [Fig 18B].

4.4.3

Voluntary Oral Methamphetamine Consumption

Having placed n=14 mice per sex on VOMA (total n=28) [Fig18C], we observed that
approximately 2/3 [n=9 mice per sex] of mice fell into a consistent and equivalent administration
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rate, and that the remaining 1/3 of mice consumed significantly different (higher and lower vs the
average consumer). A two-way repeated measures ANOVA of MA consumption between Low
male VOMA consumers [n=5; 2.611 mg/kg/day over 28d +/-0.39 SEM] and medium male
VOMA consumers [5.811 mg/kg/day over 28d +/-0.59 SEM] over 28d of VOMA showed a
significant overall effect of consumption rate [F1,12=15.46, p<0.01]. A two-way repeated
measures ANOVA of MA consumption between Low female VOMA consumers [n=2; 1.283
mg/kg/day over 28d +/-0.15 SEM] and medium female VOMA consumers [6.01 mg/kg/day over
28d +/-0.62 SEM] over 28d of VOMA showed a significant overall effect of consumption rate
[F1,9=17.41, p<0.01]. A two-way repeated measures ANOVA between High female [n=3; 8.4
mg/kg/day over 28d +/-0.91 SEM] and average female consumers [see above for statistics] over
28d of VOMA showed a significant overall effect of consumption rate [F1,10=5.719, p<0.05]. To
compare equivalent rates of voluntary MA consumption between sexes, our study focuses on the
behavioral and molecular results from the 2/3 of mice that displayed this average (medium)
consumption rate across males and females.
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Figure 17. Escalation VOMA model produces equivalent, sustained MA consumption in
both male and female mice. The study lasted 8 weeks, with acclimation and shaping during
weeks 1-2; VOMA during weeks 3-6; behavioral analyses during weeks 7-8 (A). Control mice
expose to vehicle (Ensure) only, consumed all baits delivered over 28 days of the VOMA study
design (B). Escalation VOMA produces equivalent consumption of MA across medium male
(average 5.8mg/kg MA/day over 28d) and medium female mice (average 6.0 mg/kg MA/day
over 28d) (C). A Two-way ANOVA within-subjects analysis revealed an overall interaction
effect of sex and day but no significant post-hoc effects on any given day. From a cohort of 28
mice (n=14 from each sex) enrolled into VOMA, n=9 mice of each sex fell into the medium
consumption group, while n=5 of each sex fell into high and/or low consumption groups. Body
weight were tracked across all study weeks and a mixed model ANOVA revealed only overall
sex and week differences between group body weights (D).
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Following the escalation phase of VOMA, our analyses show that medium male mice consume
an average of 7.68mg/kg MA/day (+/- 0.31 SEM) and medium female mice consume an average
8.2mg/kg MA/day (+/-0.12 SEM) over the last 18d of VOMA; 5.8mg/kg/day MA (+/-0.59 SEM)
and 6.0mg/kg MA/day (+/- 0.62 SEM) over 28d for medium male and medium female mice,
respectively. When analyzing daily MA consumption between average male and average female
mice over the 28d VOMA regimen (Figure 18C), a two-way repeated measures ANOVA shows
no significant overall effect between sexes (F1,16=0.08, p=0.782), but both show a significant
overall effect of day (F27,432=56.6, p<0.001) and a significant overall interaction effect of sex and
day (F27,432=1.82, p<0.01). Upon closer analysis of the last 18d of VOMA, there was no
significant overall effect between sexes (F1, 16=0.25, p=0.62) but a significant effect of day
(F17,272=4.569, p<0.001) and a significant interaction effect of sex and day (F17,272=2.12, p<0.01).
There were no post-hoc effects between groups.

4.4.4

Body weights

Body weights were tracked daily for all groups across all 8 weeks of the study [Fig 18D]. A
repeated measures multivariate ANOVA of body weights across weeks revealed a significant
overall effect of time (F7,27=133.1, p<0.001), a significant overall effect of sex (F1,33=150.1,
p<0.001), no overall effect of MA (F1,33=0.697, p>0.5), no overall effect of MA dose by sex
(F1,33=0.106, p>0.5), and a significant overall interaction effect of time by MA dose
(F14,56=1.886, p=0.048) and a significant overall interaction of time by sex (F7,27=4.089,
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p<0.01). These results indicate that within the study, body weights were affected more so in
relation to time and were different between sexes. There is no strong indication that MA
exposure affected the body weights of mice at any given point in the study. The overall
interaction of time by MA dose is likely due to the lower body weights of High Female VOMA
mice.

4.4.5

Tail suspension and Elevated Plus Maze Assessments

Possible effects of VOMA on depression were assessed by the tail suspension test. A two-way
ANOVA of time spent immobile during the tail suspension test [Fig19A], across sex and drug
treatment, revealed no significant overall effect of sex (F1,25=2.67, p>0.1), no significant overall
effect of drug (F1,25=0.7, p>0.4), and no significant overall interaction effect of sex by drug
(F1,25=0.6, p>0.4). This result indicates that Escalation VOMA had no effect on eliciting
depressive phenotypes in these mice. Effects of VOMA on locomotion and anxiety were
examined on the EPM. A two-way ANOVA of closed-arm entries [Fig 19B] on the EPM
revealed a significant overall effect of sex (F1,25=5.67, p<0.05), no significant overall effect of
drug (F1,25=0.039, p>0.8), and no significant overall interaction effect of sex by drug
(F1,25=0.5, p>0.4). Post-hoc analyses revealed a significant difference between male and female
VOMA mice (t25=2.53, p<0.05). A two-way ANOVA of open-arm entries on the EPM [Fig
19C] revealed no significant overall effect of sex (F1,25=1.35, p>0.2), a significant overall effect
of drug (F1,25=5.96, p<0.05) and no significant overall interaction effect of sex by drug
(F1,25=0.006, p>0.9). These results show that VOMA increased exploratory and ambulatory

105

behavior in females (increased closed arm entries) while both sexes exhibited less anxiety
following VOMA (increased open arm entries).
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Figure 18. Escalation VOMA increases ambulatory behavior on the elevated plus maze.
Following VOMA, mice underwent the tail-suspension test and results revealed no effect of drug
or sex on immobility in this assessment, indicating that VOMA does not produce a depressive
phenotype in either sex (A). Analysis of elevated plus maze activity shows female VOMA mice
were more ambulatory as seen in their number of entries into closed arms (B) and in analyzing
the entries into open arms, VOMA mice had significantly more than control mice (C). (*p<.05)
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4.4.6

Working Memory Assessment

Working-memory performance on the radial arm maze was analyzed across bait pairs, i.e. arms
visited to collect the first set of baits (baits 1-2), second set baits (baits 3-4), third set of baits
(baits 5-6) and fourth set of baits (baits 7-8). Within each bait-pair trial, the number of correct
arms (always n=2) was divided by the total number of arms visited to collect the bait pair. A
repeated measures three-way ANOVA of RAM performance between treatments (medium
VOMA and control), sexes and across all bait pairs revealed an overall effect of bait pair
(F3,75=106.4, p<0.001), no overall effect of treatment (F1,25=0.2018, p>0.6), no overall effect
of sex (F1,25=0.32, p>0.5), no overall interaction effect of bait pair and sex (F3,75=2,12, p>0.1)
a marginal overall interaction effect of bait pair and treatment (F3,75=2.65, p=0.055), no overall
interaction effect of treatment and sex (F1,25=1.53, p>0.2) and no overall interaction effect of
sex, treatment and bait pair (F3,75=0.6, p>0.6). To more closely examine group comparisons,
two-way ANOVAS were run to compare RAM performance across sex and treatments. A
repeated measures two-way ANOVA of VOMA mice performance [Fig 20A] for each bait pair
revealed no significant overall effect of sex (F1,16=1.75, p>0.2), a significant overall effect of
bait-pair (F3,48=90.55, p<0.001) and a significant overall interaction effect of sex by bait
(F3,48=3.48, p<0.05). Post-hoc analyses revealed a significant effect of sex between VOMA
mice on bait-pair 5-6 (t64=2.94, p<0.05). A repeated measures two-way ANOVA of the
performance of Control mice [Fig 20B] within each bait pair revealed no significant overall
effect of sex (F1,9=0.31, p>0.5), a significant overall effect of bait-pair (F3,27=32.3, p<0.001)
and no significant overall interaction effect of sex by bait (F3,27=0.35, p>0.79). Post hoc
analyses revealed no significant differences between groups on any given bait trial. However, in
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VOMA mice there was a significant difference between sexes midway during the assessment
when the working memory load is heavy (bait pair 5-6) with females showing poorer
performance than males. In addition, female mice exhibited a significantly greater number of
working-memory errors committed during the RAM assessment, as a percent of controls,
compared to males (t16=2.49, p<0.05) [Fig 20C]. These results highlight that Escalation VOMA
affects working memory in females but not males.
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Figure 19. Radial Arm Maze working memory assessments. The 8-arm radial arm maze
working memory assessment was used to test the short-term memory capacities of mice
following VOMA. VOMA produced sex differences in performance of baits 5-6 (of total 8), with
male mice performing better than female mice (A). Control treatment showed no significant sex
differences in performance throughout the assessment (B). Female VOMA mice exhibit
increased percent working-memory errors compared to male VOMA mice (C). (*p<.05)
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4.4.7

Dopamine signaling markers

Whole hippocampi were processed for western blot analyses. Cytosolic and synaptic fractions
were processed for dopamine marker expression, as MA is known to preferentially affect
monoaminergic pathways like the dopamine system 45. All values were corrected for gapDH. A
two-way ANOVA of synaptic DAT [Fig 21A] revealed no significant effect of sex (F1,14=3.6,
p>0.05), or drug (F1,14=1.17, p>0.2), but a significant interaction effect of sex by drug
(F1,14=6.19, p<0.05). Post-hoc analyses revealed significant differences between male control
mice and male VOMA mice (t14=2.65 p<0.05) and between male and female control mice
(t14=2.97, p<0.05). A two-way ANOVA of cytosolic TH [Fig 21B] revealed a significant effect
of sex (F1,21=18.68, p<0.001), no significant effect of drug (F1,21=0.14, p>0.7), or interaction
effect of sex and drug (F1,21=0.056, p>0.8). Post-hoc analyses revealed significant differences
between male and female mice in control (t21=2.96 p<0.05) and VOMA (t21=3.2 p<0.01)
treatments. A two-way ANOVA of synaptic D1 [Fig 21C] revealed a significant effect of sex
(F1,23=11.66, p<0.01), a significant effect of drug (F1,23=11.77, p<0.01), and a significant
interaction effect of sex and drug (F1,23=9.14, p<0.01). Post-hoc analyses revealed significant
differences between male VOMA mice and male control mice (t23=4.1 p<0.001) and male
VOMA mice and female VOMA mice (t23=5.8 p<0.001). A two-way ANOVA of synaptic D2
[Fig21D] revealed no significant effect of sex (F1,14=1.399, p>0.2), or drug (F1,14=0.1045,
p>0.7), and a significant interaction effect of sex and drug (F1,14=8.051, p<0.05). Post-hoc
analyses revealed a significant difference between male VOMA and male control mice (t14=2.9
p<0.05).
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Figure 20. Escalation VOMA produces sex differences in hippocampal D1, D2 and DAT
expression levels. Male and female mice exhibit different basal levels of hippocampal DAT and
escalation VOMA decreases levels in males but not females (A). Male mice show higher levels
of TH across control and VOMA conditions compared to females (B). Escalation VOMA
increases hippocampal D1 levels in male mice but not in female mice (C). Escalation VOMA
decreases hippocampal D2 levels in male mice but not in female mice (D). (*p<.05; **p<.01)
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4.4.8

ERα and Akt/GSK3β signaling pathways

Hippocampal cytosolic and synaptic fractions were analyzed for neuroprotective signaling
pathways and estrogen receptor alpha (ERα) to examine the role of hormonal fluctuations on
VOMA-induced neurochemical changes. All values were corrected for gapDH. A two-way
ANOVA of synaptic ERα [Fig 22A] revealed no significant effect of sex (F1,19=1.528, p>0.2), a
significant effect of drug (F1,19=4.97, p<0.05), and a significant interaction effect of sex and
drug (F1,19=8.317, p<0.05). Post-hoc analyses revealed significant differences between male
VOMA mice and male control mice (t19=2.57 p<0.01) and male VOMA mice and female
VOMA mice (t19=3.48 p<0.01). A two-way ANOVA of cytosolic AKT [Fig 22B] between
revealed no significant effect of sex (F1,19=0.086, p>0.7), a significant effect of drug
(F1,19=4.692, p<0.05), and a significant interaction effect of sex and drug (F1,19=7.91, p<0.05).
Post-hoc analyses revealed significant differences between male VOMA mice and female
VOMA mice (t19=2.47 p<0.05) and female control mice and female VOMA mice (t19=3.5
p<0.01). A two-way ANOVA of cytosolic phospho-AKT [Fig22C] revealed a significant effect
of sex (F1,19=16.85, p<0.001), a significant effect of drug (F1,19=10.07, p<0.01), and no
significant interaction effect of sex and drug (F1,19=0.2687, p>0.05). Post-hoc analyses revealed
significant differences between male VOMA mice and female VOMA mice (t19=3.68 p<0.01)
and female control mice and female VOMA mice (t19=2.59 p<0.05). A two-way ANOVA of
synaptic GSK3β [Fig 22D] revealed a significant effect of sex (F1,19=21.95, p<0.001), no
significant effect of drug (F1,19=0.065, p>0.8), or interaction effect of sex and drug
(F1,19=1.81, p>0.1). Post-hoc analyses revealed significant differences between male VOMA
mice and female VOMA mice (t19=4.81 p<0.001). A two-way ANOVA of synaptic phospho-
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GSK3 [Fig 22E] revealed a significant effect of sex (F1,19=6.841, p<0.05), no significant effect
of drug (F1,19=1.904, p>0.1), or interaction effect of sex and drug (F1,19=0.175, p>0.6). Posthoc analyses revealed no significant differences between groups. A two-way ANOVA of
synaptic phospho-GSK3β/GSK3β corrected ratios [Fig 22E] revealed no significant effect of sex
(F1,20=1.159, p>0.2), a significant effect of drug (F1,20=4.956, p<0.05), and no significant
interaction effect of sex and drug (F1,20=4.025, p>0.05). Post-hoc analyses revealed significant
differences between male VOMA mice and female VOMA mice (t20=2.5 p<0.05) and between
male VOMA mice and male control mice (t20=2.9 p<0.05).
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Figure 21. Escalation VOMA produces sex differences in hippocampal ERα-GSK3βpathway activity. Male and female mice exhibit different levels of hippocampal ERα pathway
activity following Escalation VOMA, with male mice showing increased expression of
neuroprotective markers ERα (A), AKT (B), and pAKT (C) over female VOMA mice. AKT
activation is known to directly mediate activation of GSK3β, whose phosphorylation is
neuroprotective and dephosphorylated state is pro-apoptotic. Escalation-VOMA increases total
GSK3β in females (D) but not males, dysregulates pGSK3β, and increases pGSK3β to total
GSK3β ratios in males but not females, indicating that escalation produces sex-specific
neuroprotection only in males. (*p<.05; **p<.01)
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4.4.9

D-prostanoid receptor 1, 2 (DP1/DP2 receptor)

Hippocampal cytosolic and synaptic fractions were analyzed for prostaglandin receptor
expression, to examine the effects of VOMA on prostaglandin-mediated signaling. All values
were corrected for gapDH. A two-way ANOVA of cytosolic COX-2 [Fig 23A] revealed a
significant effect of sex (F1,21=4.569, p<0.05), a significant effect of drug (F1,21=5.422,
p<0.05), and no significant interaction effect of sex and drug (F1,21=0.787, p>0.3). Post-hoc
analyses revealed no significant differences between groups. A two-way ANOVA of synaptic
DP1 [Fig23B] revealed a significant effect of sex (F1,17=11.01, p<0.01), no significant effect of
drug (F1,17=0.288, p>0.5), or interaction effect of sex and drug (F1,17=3.09, p>0.05). Post-hoc
analyses revealed a significant difference between male VOMA mice and female VOMA mice
(t17=4.1 p<0.01). A two-way ANOVA of synaptic DP2 [Fig 23C] revealed no significant effect
of sex (F1,22=1.159, p>0.2), drug (F1,22=2.92, p>0.5), or interaction effect of sex and drug
(F1,22=2.386, p>0.05). Post-hoc analyses revealed a revealed no significant differences between
groups.
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Figure 22. Escalation VOMA produces sex differences in hippocampal DP1 but not COX-2
or DP2 levels. In response to Escalation VOMA, Hippocampal COX-2 levels do not change
significantly compared to controls (A). However, DP1 levels increase in female mice but not in
male mice (B). Hippocampal DP2 levels do not show significant changes in male or female
mice, with or without VOMA (C). (**p<.01)
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4.4.10

Hippocampal PKCι/λ and PKMζ

Hippocampal cytosolic fractions were analyzed for atypical protein kinase c expression, PKMζ,
known to play a major role in learning and memory 170, in order to examine the underlying
mechanisms for VOMA induced memory deficits. All values were corrected for gapDH. A twoway ANOVA of cytosolic PKCι/λ [Fig 24A] revealed no significant effect of sex (F1,22=0.209,
p>0.6), drug (F1,22=0.014, p>0.9), or interaction effect of sex and drug (F1,22=0.532, p>0.4). A
two-way ANOVA of cytosolic PKMζ [Fig 24B] revealed a significant effect of sex
(F1,23=6.775, p<0.05), no significant effect of drug (F1,23=0.436, p>0.5), or interaction effect
of sex and drug (F1,23=1.447, p>0.2). Post-hoc analyses revealed a significant difference
between male VOMA mice and female VOMA mice (t23=2.98 p<0.05).
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Figure 23. Escalation VOMA produces sex differences in hippocampal PKMζ. Escalation
VOMA produces no differences in PKCι/λ across male or female mice (A). Escalation VOMA
produces sex differences in hippocampal PKMζ levels, with females showing a significant
reduction compared to males following VOMA (B). (*p<.05)

119

4.4.11

κ-Opioid receptor

Hippocampal and NAc synaptic fractions were analyzed for κOR expression in order to
characterize the molecular signaling underlying addiction as perpetuated by VOMA. All values
were corrected for gapDH. A two-way ANOVA of hippocampal synaptic κOR [Fig 25A]
revealed no significant effect of sex (F1,13=1.358, p>0.2), no significant effect of drug
(F1,13=1.752, p>0.2), and a significant interaction effect of sex and drug (F1,13=12.32, p<0.01).
Post-hoc analyses revealed significant differences between male control mice and female control
mice (t13=3.06 p<0.05) and between male control mice and male VOMA mice (t13=3.74
p<0.01). A two-way ANOVA of NAc synaptic D1 [Fig 25B] revealed a significant effect of sex
(F1,17=40.69, p<0.001), no significant effect of drug (F1,17=4.23, p>0.05), or interaction effect
of sex and drug (F1,17=0.9, p>0.3). Post-hoc analyses revealed significant differences between
male control mice and female control mice (t17=3.32 p<0.01) and between male VOMA mice
and female VOMA mice (t17=6.34 p<0.001). A two-way ANOVA of NAc synaptic κOR [Fig
25C] revealed no significant effect of sex (F1,17=0.3478, p>0.5), no significant effect of drug
(F1,17=0.026, p>0.8), and a significant interaction effect of sex and drug (F1,17=8.153, p<0.05).
Post-hoc analyses revealed a significant difference between male VOMA mice and female
VOMA mice (t17=2.98 p<0.05).
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Figure 24. Escalation VOMA produces increased NAc κOR pathway activity. In response to
Escalation VOMA, Hippocampal κOR levels are significantly decreased in male mice but not in
female mice (A). Accumbal D1 levels are significantly decreases in female mice, with and
without VOMA compared to males (B). Accumbal κOR levels are significantly increased in
female mice after VOMA (C) indicating that differences in D1 signaling can be explained partly
by κOR-dependent signaling that affects the dopamine system in this region. (*p<.05; **p<.01)
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4.5

Discussion

and females (6-8 weeks of age). Based on medium VOMA consumers [average 5.8-6mg/kg
MA/day over 28d; 7.6-8.2 mg/kg/day over the last 18d] across males and females, we created
cohorts that consumed equivalent amounts of MA during the 28d MA-treatment period. Our
results show sex-specific effects on behavior and neurochemical expression of various markers
in the hippocampus. Behavioral results show that VOMA did not affect depression, was
associated with increased anxiety in both sexes, and VOMA-females developed workingmemory deficits, but males did not. Analysis of dopamine markers show increased D1 in VOMA
males compared to control males and VOMA females. There were no changes in DAT, TH or
D2. Additionally, ERα increased in VOMA males including the downstream activation of pAkt
and the ratio pGSK3β/GSK3β but not in females. These results indicate that VOMA males, but
not females, have enhanced neuroprotection. In contrast, VOMA females show enhanced DP1
and reduced DP2, a PGD2 receptor specific expression pattern reflecting heightened response to
neuroinflammatory insults that is not observed in males. VOMA females also demonstrate
enhanced

-opioid receptor expression in the NAc indicative of negative symptomology

associated with drug withdrawal but males did not. These results highlight the sex-specific
vulnerability of chronic VOMA and the differential signaling pathways that are activated
between sexes during adolescence and suggest a role of sex-specific treatments for addiction.

4.5.1

Chronic VOMA impairs female working memory but not males
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impulse control 25-27, 267. Many of these results are also shown in rodent studies 22, 268. MAinduced working memory deficits in male mice show sustained effects for up to 7 weeks after a
neurotoxic dose of MA and following 28d VOMA without escalation 189, 258. Our working
memory assessment of adolescent mice shows working memory deficits in VOMA females as
compared to control females, but such VOMA-induced deficits were not present in males. This
effect is consistent with other reports identifying female enhanced sensitivity to MA 253-254, 269.
However, following chronic or long-access to MA, both males and females show memory
deficits but females exhibited higher MA intake and greater relapse to MA-seeking 253. Taken
together, increased drug consumption combined with greater escalation demonstrates that
females are more sensitive to the primary rewarding aspects of psychostimulant drugs which can
disrupt reward driven memory tests 269. The superior performance of VOMA males compared to
VOMA females may be the result of the MA-induced increase in D1 expression. For example,
increased striatal D1 has been shown to engender a readiness to respond to reward in animals
pretreated with MA 270. Increased cortico-striatal D1 activity is predictive of reward-based
learning 271, and increased sensitivity in this D1 pathway can modulate working memory
performance 272. Hippocampal-dependent working memory is also modulated by discrete
changes in D1 activation 273.

4.5.2

VOMA differentially affects Dopamine-related markers across sexes

Our results show that VOMA did not alter TH, D2 or DAT expression in females, while males
show decreases in DAT and D2 with increases in D1 compared to controls. This patterns
suggests differential neurotoxic effects between sexes as D2 and DAT are modulated by MA,
and D2 antagonist have been shown to reduce neurotoxic effects of binge doses 118 as do DAT
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inhibitors 274. Thus, lower levels of D2 and DAT could reflect neuroprotection in males. Previous
studies have shown that escalating doses of MA offer some neuroprotection and/or slow the
expression of neurotoxicity 19-20, 74. This interpretation is consistent with our previous VOMA
study in males where we identified decreases in both TH and DAT following 28 VOMA without
escalation 189. Our results with TH and DAT also indicate a sex-difference between control
groups. This effect is in contrast to DAT levels reported in human studies showing higher DAT
expression in females than males 275-277. Rodent studies have been less consistent, with some
studies demonstrating greater DAT expression in females 278-280, and other showing no basal
differences 281-283. Additionally, some studies have shown that male DAT expression in striatum
is more responsive to early life stress 284 and to high doses of MA 78. In striatum, DA
concentration are not different between sexes however; males show great numbers of TH
immunoreactive cells in the substantia nigra pars compacta compared to females 285-286. While no
evaluation of TH or DAT across sexes has been done in the hippocampus, these current data
indicate sex-specific expression differences in hippocampus for dopamine markers.

VOMA also induced a significant increase in D1R expression in males but not females. Several
reports show that MA-induced D1 activation is neuroprotective in the hippocampus by
suppressing glutamatergic neurotransmission 130 and can reduce NMDA receptor mediated Ca2+
currents in hippocampal neurons, 131, in striatal neurons 127, and in producing inhibition on Ntype voltage-gated calcium channels 132. In contrast, reports show that a D1R antagonist can
reduce the neurotoxic effects of binge doses of MA 118. MA-induced D1R activation can also
exacerbate glutamate toxicity 129. Therefore, it is possible that alterations in other receptors
dictate whether increased D1R-levels are beneficial or detrimental. It is interesting that males
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significantly upregulate D1R but females do not. To date, we believe this is the first report
identifying differential expression of MA-induced D1 across adolescent animals, suggesting that
D1 could be a useful sex-specific therapeutic target for MA neurotoxicity.

4.5.3

The role of dopamine induced expression on estrogen receptor α (ERα)

Our results show males increase ERα following VOMA but females do not. Several reports have
shown that estradiol can elevate ERα expression and have neuroprotective effects on MA 287-289
and on mitigating MA-induced cognitive deficits 290. However, fewer studies have investigated
the role of dopamine on estrogen receptors as we have here. While we do not know the
mechanism explaining why this sex difference occurs, several reports show that ERs can also be
activated in the absence of ligand. In vitro studies show that in the absence of estradiol, ERs are
activated by several different neurochemical factors involving: EGF 291, IGF-I 292, caveolin-1 293,
and activators of the protein kinase A and protein kinase C pathways 294 resulting in ERdependent gene transcription. Uterine EGF 295 and IGF-I 296 also result in ER-dependent gene
transcription that can be blocked by an ER antagonist in vivo. Furthermore, ERs can be activated
in vitro in the absence of estradiol by dopamine 297-299, and in vivo 300. Based on these studies, we
suggest that the elevated expression of D1 in VOMA-treated males is presumably enhancing the
ERα expression in a sex-specific manner.

4.5.4

VOMA-induced sex differences in GSK3β and Akt signaling pathways associated with

ERα
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Estradiol and the IGF-1 receptor (IGF-1R) interact through ERα, allowing for the formation of a
multimolecular complex composed by ERα, IGF-1R and components of this downstream
signaling pathway such as, PI3K, Akt, and GSK3β 301-303. This ERα/IGF-1R interaction regulates
PI3K-Akt-GSK3β-β-catenin signaling by estradiol 287, 302. It has been shown that inhibition of
PI3K signaling abolishes the hippocampal neuroprotective actions of estradiol 304-305. In addition,
the Akt activation by estradiol controls expression of the anti-apoptotic molecule Bcl-2 via the
cAMP-response element-binding protein (CREB) 306-307. Downstream, Akt phosphorylates the
glycogen synthase kinase 3β (GSK3β) and BAD proteins, thereby inhibiting their pro-apoptotic
functions 303 inducing the activation of neuronal survival pathways 308. These studies are
consistent with our results showing VOMA males increasing ERα together with sustaining
higher levels of phosphorylated Akt and the pGSK3βGSK3β ratio and support a role for the
neuroprotective effects of the GSK3β pathway as sexually dimorphic with chronic MA. GSK3β
is negatively regulated by the phosphorylation on its serine 9 (Cohen and Frame, 2001). In
contrast, 40mg/kg IP MA following 7d abstinences produces greater neurotoxicity in males with
decreased GSK3β and pAkt compared to females 78. This report suggests that at high doses of
MA, females may have greater capacity for neuroprotection than males, while the opposite may
be true for low or voluntary consumption rates of MA between sexes. Nevertheless, our results
show a sex-specific effect of GSK3β. While no other reports have identified differences in
expression levels of this marker, one report has identified differential activation of this signaling
pathway mediated in leukemic stem cell therapy 309.

4.5.5

Enhanced D-prostanoid receptor 1 (DP1 receptor) in females following VOMA
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We evaluated the expression of both the DP1 and DP2 receptors following VOMA as an
indicator of response to neuroinflammation 99. Prostaglandins initiate signaling through multiple
receptors that have both proinflammatory and anti-inflammatory effects. Prostaglandin D2
(PGD2), the most abundant prostaglandin in the brain 310, is considered anti-inflammatory when
it signals through the D-prostanoid receptor 1 (DP1 receptor) present on myeloid cells but
proinflammatory when it binds to the DP2/CRTH2 receptor on Th2 CD4 T cells 311-312.
PGD2/DP1 signaling triggers G protein activation and cAMP production and has been associated
with neuroprotection following diverse insults 99, 156, 313. In addition, a PGD2 derivative, 15dPGJ2, also signals through the DP1 receptor, inhibiting the inflammatory response 314. Inhibiting
the DP1 receptor retards resolution of inflammation in macrophages 315. Conversely, the
activation of DP2 receptor is associated with activation of proapoptotic signaling 316. Based on
these reports, our data suggest that the differential expression observed in VOMA-females is a
response to enhanced neuroinflammation, this data further suggests that males are not activating
this signaling pathway for neuroprotection. CRTH2 signaling leads to GSK3β phosphorylation in
TH2 lymphocytes, suggesting a role for this receptor in neuroprotection 317. However, the cellspecific localization of this receptor could determine its protective or pro-inflammatory role as
the activation of DP2/CRTH2 is associated with activation of proapoptotic signaling in
cardiomyocytes 316. Based on these reports our data suggests that the differential expression of
DP1 observed in VOMA-females is in response to enhanced neuroinflammation. The data
further show that males are not activating this signaling pathway for neuroprotection. This
hypothesis is consistent with our observations of increased neuroprotection via enhanced AKTpGSK3β found in males but not females.
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4.5.6

VOMA induces sex-specific downregulation of PKMζ in the hippocampus

Our analysis of sex-specific effects of VOMA include PKM and PKCι/λ, synaptic plasticity
markers associated with learning and memory 91, 318. PKM is important for both late-phase LTP
164 and

long-term memory maintenance across various learning paradigms 88, 91, 165-166. PKM plays

major roles in the trafficking of AMPA receptors that sustain LTP processes

168-169.

Our results

show that PKM was significantly reduced in female VOMA mice compared to male VOMA mice
and showed a trending decrease compared to controls. These results indicate that synaptic
plasticity marker expression was differentially affected between sexes to produce the working
memory deficit in female VOMA mice. Previously, it has been shown that PKCι/λ acts as a
compensatory AMPAr trafficking enzyme in animal models where PKM was knocked-out, but
in wildtype mice, PKM remains a pivotal enzyme regulating AMPAr trafficking, LTP, and
memory 170. Still unknown is how PKCι/λ may undermine AMPAr trafficking and LTP deficits in
models of stress and drug addiction, where PKM is consistently affected

89, 189, 258

The current

study shows that PKCι/λ, unlike PKM, remains unchanged following VOMA in both male and
female mice. This result suggests that following VOMA, PKCι/λ may act to partially rescue
AMPAr and LTP deficits brought on by PKM. This hypothesis should be tested in future studies.

4.5.7

Methamphetamine-induced modulation of κ-opioid receptor (κOR) and D1 in NAc

We investigated -opioid receptor (κOR) expression in the NAc following VOMA as part of the
ventral hippocampus-NAc circuit that participates in stimulant-induced expression of drug
addiction behaviors 50 The reciprocal connections between the NAc and the hippocampus
suggest that individual drug preferences could also influence the rewarding properties associated
with spatial learning. Our results show that VOMA females increase κOR in the NAc compared
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to VOMA males. The expression of κOR in the NAc is associated with the negative affect of
drug withdrawal and for the repeated, compulsive-like drug behavior 319-320. D1 activation
regulates prodynorphin, the precursor of dynorphin, the endogenous ligand for κOR 321. ORs
are located on striatal dopaminergic and glutamatergic terminals 322-323. Activation of dynorphin
systems feedback to decrease dopamine release and contribute to the dysphoric syndrome
associated with cocaine dependence 324-327, and long access to MA 319. Consistent with our data,
chronic MA leading to escalating consumption depends on the activation of the κOR system in
the NAc shell 319. Selective inhibition of κOR blocks the development and/or expression of
escalation of intravenous heroin intake 328, excessive alcohol self-administration 329 and MA selfadministration 319. Conversely, κOR agonists have been shown to induce dysphoric-like states in
rodents and humans. This state in the ventral striatum may be driving escalation of intake via a
negative reinforcement mechanism 319, 330. Our results suggest that females may have a
vulnerability to dysphoric-mediated effects of κOR based on lower basal levels of D1 in the NAc
compared to males. This hypothesis is consistent with 331 demonstrating that escalation of
cocaine intake is driven by decreases in phasic dopamine release in the ventral striatum and that
normalization of this state by the dopamine precursor l-DOPA can eliminate the escalation of
cocaine intake. Thus, κOR acts as a presynaptic regulator of dopamine release, and, when the
κOR system becomes sensitized by repeated psychostimulant use, it creates a state of deficient
presynaptic dopamine release altering not only the rewarding properties of drugs, but also the
food reward earned during spatial learning.

4.6

Conclusion and Clinical Implications
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To determine how chronic access to MA differentially affects the hippocampus and NAc across
adolescent male and female mice, we used a recently developed VOMA model 189. The findings
show that with 10 days of escalating dosing, the males show reduced neurotoxic effects of MA
compared to previously published results without escalation. Additionally, the VOMA females
show exacerbated working memory deficits compared to VOMA males and show a distinctly
different pattern of neurochemistry compared to males. Males increase D1, ERα pAkt, and
pGSK3β /GSK3β ratio, suggesting neuroprotection, but females do not. Conversely, females
show an increase in DP1 levels and a concomitant increase in κOR in NAc suggesting a response
to increased neuroinflammation and elevated dysphoria that males do not. Presently little
evidence exists to understand the differential drug seeking and vulnerabilities between sexes.
Few studies have examined the long-term access drug seeking profiles in addition to their
underlying mechanisms. The current work highlights differential activation of signaling
pathways between males and females that have consumed voluntarily equivalent amounts of MA
for 28d. The increased vulnerability of the
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Figure 25. Escalation VOMA produces distinct behavioral and molecular responses
between male and female mice. In response to Escalation VOMA, female mice exhibit
compromised molecular signatures, including deficits in synaptic marker expression, increased
neuroinflammatory activity, and decreased neuroprotective pathway activity that may underlie
the cognitive deficits evidenced on the radial arm maze. Conversely, male mice that underwent
Escalation VOMA exhibit increased neuroprotective activity, and no significant deficits in
synaptic marker expression or neuroinflammatory activity, that result in no change in cognitive
performance. This model has revealed a specific role for escalating methamphetamine doses to
produce neuroprotection but only in male subjects. Female subjects are revealed to be susceptible
to MA’s negative effects on cognition and the neurochemistry underlying behavioral
performance.
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CHAPTER 5: CONCLUSIONS
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5.1 VOMA as a naturalistic model of Methamphetamine abuse

The VOMA model has offered a new method to assess the voluntary consumption rates in a chronic
MA exposure design. VOMA allows mice to titer the amount of drug administered in a given
administration window, as reflected by the sustained level of MA consumed over several weeks.
It is worth noting that within VOMA, mice do not consume all the MA baits delivered on any
given day. As seen in our 28d and escalation models, on average, mice consume about half the
total mg/kg MA made available. This indicates that although mice may want to consume MA via
VOMA, this model does not produce mice that binge on MA, on any given day or throughout the
administration period. Future studies should focus on the emotive, behavioral, and neural
mechanisms that allow mice to self-regulate their MA consumption rates in VOMA.

Furthermore, the VOMA models have proven useful in producing specific hippocampal-dependent
cognitive impairments, as assessed by our RAM tasks. This behavioral deficits indicate that
chronic MA abuse has the potential to affect this brain region, and further, that VOMA is useful
in characterizing these effects where other models, such as self-administration, may have failed.
In contrast to previous work on the cognitive effects of neurotoxic MA 1, VOMA more closely
models natural MA consumption as it may occur in some populations. Specifically, I hypothesize
that although VOMA may not be able to accurately depict the most addicted, highest consuming
MA abusers, it can model the regular, chronic and moderate MA abusers. These populations may
include frequent partiers, women seeking to dramatically lose weight and increase productivity,
and even professionals looking to boost their day-to-day work output.
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Our experiments have revealed that with VOMA, we can model preference for MA as seen in
human populations. The use of forced MA administration in animal models has provided
mechanistic understandings of the molecular and physiological effects that the drug has on the
brain2. The current body of work has provided the next step in understanding the voluntary
development of MA addiction. As my data shows, VOMA can produce a range in consumers (See
Chapter 3). Intuitively, this result translates to our understanding of MA addiction in humans, as
not all human MA consumers are considered highly dependent addicts 332. Thus, the true range in
human MA consumption likely follows a normal distribution, with very low and very high
consumers at the ends of the population, with the majority of consumers falling in between these
extremes. From my experiments, it seems very plausible that we have been able to mimic this
hypothetical human distribution in mice. Through various experimental set-ups, we have produced
low consumers, average consumers, and (not reported) the occasional super consumers. As
mentioned above, more work is needed to understand the neural, emotive and/or behavioral
mechanisms that produce this distribution in consumption rates. Preliminary work on this question
has been shown in Chapter 3, where intracellular AKT-GSK3β and KOR activity has been
measured and found to be dysregulated in female VOMA mice. Future experiments should be
designed to target these pathways pharmacologically to assess output measure in behavior, DA
toxicity, synaptic plasticity and neuroinflammation.

Despite its reliance on oral-dosing, a route not considered to be wholly reflective of consumption
by addicted individuals, VOMA is nonetheless a useful model that provides us with non-invasive
and effective MA administration. Consistent deficits in RAM working memory, despite the design
of VOMA experiments, indicate a loss of normal function in striatal-hippocampal signaling. This
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is directly in line with decreases in dopamine marker expression in the hippocampus. These data
show that VOMA is effective in producing the behavioral and molecular deficits produced by
previous administration models. The critique against the oral route for this psychostimulant can be
attributed to the notion that addicted individuals do not administer MA via this route, opting for
intravenous or intranasal administration, as discusses above. However, data on human
psychostimulant administration shows that oral administration makes a high percentage of abuse
103,

and that the half-life of MA via oral administration is not different from that of other routes

101-102.

Follow-up work on VOMA should aim to characterize the pharmacokinetics of MA

following various dosing periods, such as after 1d VOMA, 7d VOMA, 14d VOMA and 28d
VOMA at 1hr, 4hr, 8hr, and 24hr post final dose. Blood plasma and brain samples should be taken
to assess for MA content and following VOMA for these periods of time. These follow-up
experiments should help clarify the ability of VOMA to make MA available throughout the body
and brain.

5.2 Abstinence exacerbates the neuronal damage associated with Methamphetamine abuse

MA is known to facilitate dopamine neuro-transmission45 which is the underlying molecular
mechanism that produces euphoria and increases the risk for dependence and addiction333. As MA
is used to increase DA release more and more during abuse, toxicity of DA terminals and/or
compensatory signaling can lead to decreased baseline DA activity in the brain. In-vivo, this
decreased DA pathway activity can lead to physiological dependence to MA 334 as well as
psychological and behavioral shifts that mirror neurological diseases like depression 335 and
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Parkinson’s disease336, among others. Thus, it seems that the time away from MA is as important
to the progression of addiction and physiological changes that occur as a result of MA-abuse.

Abstinence, whether permanent (as in our animal models) or transient (as can be seen in human
addicts that cannot abstain), is an important factor to consider in understanding the behavior and
physiological changes that result from MA abuse. To reiterate, MA acts on the dopamine system,
and is predominantly acting to increase DA neurotransmission2. Although many of MA’s
deleterious effects occur after this main molecular activity (including DA-quinone formation, DAT
loss of function, etc.), special attention should be placed on the period of time following a period
abuse. In humans, this period could be the time between last period of abuse and the one to come.
In our VOMA model, this is the length of time following last dose and prior to tissue collection.

Our findings are illuminating. Four (4) weeks of abstinence following VOMA or bolus-MA
injections produces increased neurotoxic prostaglandin expression. This result is counter to what
was expected, as MA alone should have increased chronic neuroinflammation. However, it was
abstinence from the drug that produced this effect. The mechanisms surrounding how exactly
abstinence can increase the brain’s susceptibility to damage is unclear. Besides a need for more
in-depth molecular analyses of the development of this diseased state of the brain following
abstinence, molecular targets should be narrowed down to prevent neurodegenerative processes
such as this from being initiated. One future experiment should include the use of DAT agonists
(to increase the normal function of the molecule) and anti-inflammatories during or prior to
VOMA, as my data has shown these two pathways to become dysregulated in the brain after
abstinence. My hypothesis is that DAT loss of function (i.e. inverse agonism and depletion) could
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perpetuate the effects of abstinence after MA abuse, but that either with DAT-agonists or antiinflammatories, we could prevent total DAT loss of function or prevent the downstream effects of
increased DA availability in the synaptic cleft and then overall preventing a diseased state from
developing in the brain. This is in line with the understanding that DAT regulates dopamine
availability at synapses, and that dysregulation of this molecule disrupts dopamine-mediated
signaling2. In the context of addiction, this MA-induced DAT loss of function could underlie the
molecular mechanisms of MA physiological dependence.

5.3 Escalating doses prevent the cognitive and neurochemical deficits associated with
Methamphetamine abuse in male mice

To our surprise, the escalation VOMA model (Chapter 4) was not able to produce the behavioral
nor the neurochemical deficits in male adolescent mice produced in the static dose 28d VOMA
model (Chapter 2), despite having similar total MA consumption over 28d (see Fig 27). As was
discussed in Chapter 2, 28d VOMA using a static dose design produced spatial working memory
and learning deficits in male mice. However, escalation VOMA did not produce greater cognitive
deficits, or any at all. Upon analysis of hippocampal tissue samples, our neurochemistry results
from escalation VOMA male mice aligned with the in-vivo work, revealing non-significant
changes in tyrosine hydroxylase, no changes in neuroinflammation, and no changes in synaptic
plasticity marker expression. This was in contrast to findings from the 28d static VOMA model,
where DA toxicity, neuroinflammation, and synaptic plasticity marker expression was all affected.
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Figure 26. Total MA consumed in 28d VOMA (Chapter 2) vs Escalation VOMA (Chapter
3) in Male mice. There was no significant difference between the two groups.
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The behavioral data suggest that although mice are consuming at high rates during VOMA, they
have not yet reached stages of addiction that produce craving and depression. Thus, we can
conclude that although VOMA may produce sensitization and high rates of voluntary
consumption, the timeline or dose-design of this model is not sufficient to produce the latter stages
of addiction associated with drug seeking, craving and dysfunction. Rather these data suggest that
Escalation VOMA produces the early stages of MA abuse and addiction. Additionally, our model
uses young adult mice (aged 8 weeks at start of VOMA), and our behavioral data could reflect a
resilience in young mice to develop the behavioral deficits associated with MA exposure in older
mice. More work needs to be done to compare how old and young mice respond to VOMA.

This suggests that high rates of MA abuse may be maximally achieved through gradual
introduction to the drug. Escalation better models how humans might initiate MA abuse, by
gradual introduction to small doses of the drug. Our Escalation VOMA study has offered a more
robust method to produce sustained MA consumption, as evidenced by the decreased variability
in daily mg/kg MA consumed over the last 18d of the study. Additionally, this design is also able
to produce Low consuming mice. Of 14 male mice that went into VOMA, 9 mice fell into our
medium consumer group and 5 fell into the low consumer group. This distribution highlights the
strength of this design to produce high numbers of mice that sustain higher levels of MA
consumption. The data indicate a wider and clear split in consumption between groups and
provides a means to analyze genetic and behavioral variability (and/or drift) that produces higher
and lower consumers.
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Taken together, these results suggest that escalating doses have some intrinsic neuroprotective
qualities that protect the male brain and male behavior from a chronic MA’s detrimental effects.
The nature and source of this neuroprotection is unclear, but previous work has shown that this
phenomenon occurs in binge injection models, 19-20, associated with decreases in MA binding to
DAT and DA release. However, the underlying mechanisms that produce this change in DA
sensitivity remain unknown. This highlights the importance of MA’s action on DAT as a key factor
in the neurotoxicity following MA. Finally, it is unknown how escalating oral MA provides
protection or tolerance to MA challenges via DAT. This remains to be uncovered.

Interestingly, escalation VOMA did re-capitulate decreases in DAT expression in the
hippocampus, as seen in the 28d static VOMA model. DAT are modulated by MA and D2
antagonist have been shown to reduce neurotoxic effects of binge doses
274. Thus, lower
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as do DAT inhibitors

levels of DAT could reflect neuroprotection in males. Previous studies have shown

that escalating doses of MA offer some neuroprotection and/or slow the expression of
neurotoxicity 19-20, 74. This interpretation is consistent with the static 28d VOMA model where we
identified decrease in both TH and DAT following 28 VOMA without escalation 189. Additionally,
some studies have shown that male DAT expression in striatum is more responsive to early life
stress 284 and to high doses of MA 78.

5.4 Female mice are susceptible to the cognitive and neurochemical deficits associated with
Methamphetamine abuse
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Our Escalation VOMA model has revealed substantial sex differences in response to chronic MA
exposure. Male mice exhibit neuroprotective profiles, both behavioral and molecular, following
Escalation VOMA, but female mice show susceptibilities at these levels. Key neuroprotective
pathways are compromised in female mice.

Several reports show that MA-induced D1 activation is neuroprotective in the hippocampus by
suppressing glutamatergic neurotransmission

130,

by suppressing NLRP3 inflammasomes162 and

by reducing NMDA receptor mediated Ca2+ currents in hippocampal neurons,
neurons

127.
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and in striatal

Alternatively, others have shown that a D1R antagonist can reduce the neurotoxic

effects of binge doses of MA
glutamate toxicity

129.
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and that D1R activation following MA exposure can intensify

Thus, D1 alone cannot mediate neuroprotection or neuro-susceptibilities.

Several reports have shown that estradiol can elevate ERα expression and have neuroprotective
effects on MA

287-289

and on mitigating MA-induced cognitive deficits

290.

The mechanisms

underlying VOMA-induced upregulation of ERα in males is unknown and warrants further
investigation, but previous work suggests that protein kinase A and protein kinase C pathways 294,
as well as dopamine in vitro 297-299, and in vivo 300 can all increase ER levels. Thus, we hypothesize
that females exhibit vulnerabilities to MA as result of a failure to increase D1-dependent signaling
to parallel neuroprotective pathways. The underlying sex-differences in DA-mediated signaling in
response to MA, including the receptors activated, should be delineated in future studies.

The neuroprotective nature of ERα is derived from the signaling pathways that are initiated in
response to its activity. Estradiol and the IGF-1 receptor (IGF-1R) interact through ERα, leading
to a formation of a complex composed of ERα, IGF-1R and downstream signaling pathway
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components such as, PI3K, Akt, and GSK3β 301-303. Akt activation by estradiol regulates expression
of the anti-apoptotic molecule Bcl-2 via the cAMP-response element-binding protein (CREB) 306307. Downstream, Akt phosphorylates

GSK3β and BAD proteins, which inhibits their pro-apoptotic

functions 303 , leading to the activation of neuronal survival signaling308. Our data provide evidence
that these neuroprotective pathways are only active in males exposed to escalation VOMA, to
produce a behavioral and molecular phenotype unlike that seen in female mice (Fig 28). GSK3β
is negatively regulated by phosphorylation on its serine 9 site337. In contrast, 40mg/kg IP MA
following 7d abstinences produces greater neurotoxicity in males with decreased GSK3β and pAkt
compared to females

78.

This report suggests that high doses of MA may produce greater

neuroprotection for females than males, contrary to our escalating dose VOMA model. This
highlights the utility of our model to elucidate the effects of naturalistic MA administration to
investigate

the

underlying

molecular

mechanisms

surrounding

neurotoxicity

and

neurodegeneration. Overall, this indicates that more work is needed to characterize the role of
GSK3β pathways in MA-induced toxicity, cognitive changes and addiction in males and females.

To explore the sex differences in neuroinflammation following VOMA, we analyzed expression
levels of DP1 and DP2 receptors, endogenous protein receptors to prostaglandin ligand activity99.
Prostaglandin D2 (PGD2), the most abundant prostaglandin in the brain
PGJ2

314

310,

and a deritive 15d-

are considered anti-inflammatory when it signals through the D-prostanoid receptor 1

(DP1 receptor) present on myeloid cells but proinflammatory when it binds to the DP2/CRTH2
receptor on Th2 CD4 T cells 311-312. PGD2/DP1 signaling triggers G protein activation and cAMP
production and has been associated with neuroprotection following diverse insults

99, 156, 313.

Inhibiting the DP1 receptor retards resolution of inflammation in macrophages 315. Conversely, the
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activation of DP2 receptor is associated with activation of proapoptotic signaling

316.

Our data

suggests that the increased expression observed in VOMA-females was observed due to ongoing
neuroinflammation, which is likely not as prevalent in male mice, if at all. CRTH2 signaling leads
to GSK3β phosphorylation in TH2 lymphocytes, suggesting a role for this receptor in
neuroprotection

317.

However, the cell-specific localization of this receptor could determine its

protective or pro-inflammatory role as the activation of DP2/CRTH2 is associated with activation
of proapoptotic signaling in cardiomyocytes 316.

We also assessed levels of PKMζ and PKCι/λ, synaptic plasticity markers associated with learning
and memory 91, 318, of which PKMζ has been shown previously to be utilized differentially across
sexes for spatial memory functions262. PKMζ was significantly reduced in female VOMA mice
compared to male VOMA mice and showed a trending decrease compared to controls. PKCι/λ acts
as a compensatory AMPAr trafficking enzyme in animal models where PKMζ was knocked-out,
but in wildtype mice, PKMζ remains a pivotal enzyme regulating AMPAr trafficking, LTP, and
memory

170.

The current study shows that PKCι/λ, unlike PKMζ, remains unchanged following

VOMA in both male and female mice. This result suggests that following VOMA, PKCι/λ may
act to partially rescue AMPAr and LTP deficits brought on by PKMζ. These data reveal some of
the molecular mechanisms that underlie the behavioral deficits exhibited by females in this VOMA
model. The precise upstream mechanism that produce this result are unknown but could involve
GSK3β-dependent activity, as it is known to regulate and be regulated by synaptic plasticity338-339
and is known to regulate AMPA-receptor subunit trafficking340. Future studies should clarify the
role of GSK3β in VOMA-induced cognitive and excitotoxic deficits.
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Finally, our results show that VOMA females increase κOR in the NAc compared to VOMA
males. κOR expression in the NAc is associated with the negative effects of drug withdrawal and
with repeated, compulsive-like drug behavior

319-320.

Interestingly, κOR and D1 are linked, as

activation of D1Rs regulates prodynorphin, the precursor of dynorphin, the endogenous ligand for
κOR

321.

322-323,

κORs are located presynaptically on striatal dopaminergic and glutamatergic terminals

acting to regulate/decrease neurotransmitter release. This action of κORs can contribute to

the dysphoric syndrome associated with cocaine dependence

324-327,

and long access to MA

319.

This state in the ventral striatum may be driving escalation of intake via a negative reinforcement
mechanism

319, 330,

with increased κOR activity leading to increased dysphoria which leads to

increased drug administration to counter this syndrome with stimulant-induced euphoria. This
mechanism could explain sustained and/or escalating drug administration rates that underlie
physiological dependence under a voluntary administration context. Our results suggest that
females may have a vulnerability to dysphoric-mediated effects of κOR based on lower basal levels
of D1 in the NAc compared to males, and increased κOR in the same brain region. Future studies
should elucidate the role of κOR in the NAc to negatively couple effects of MA on cognition, as
is seen in our study. Additionally, κOR antagonists should be used to clarify its role on femalespecific molecular vulnerabilities to dopaminergic signaling via D1.
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Figure 27. Molecular Mechanisms of D1 and ERα- dependent neuroprotective signaling. In
the context of methamphetamine, specific synaptic pathways initiate signaling to promote
neuroprotection or neurotoxicity. Chapter 4 explores the contribution of these pathways in the
context of neurochemical and behavioral effects in male and female adolescent mice.
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CHAPTER 6: FUTURE DIRECTIONS
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6.1 Delineating VOMA-induced deficits from abstinence-induced deficits
The studies included into this dissertation have characterized the effects of VOMA following a
14-day or 28-day drug administration period and abstinence periods. Data from Chapter 2 and 3
indicate that our VOMA model can produce a neuroinflammatory response in the hippocampus,
following 2 weeks or 4 weeks of abstinence. It is unclear if the neuroinflammation observed is
due to MA neurotoxicity or abstinence. Additionally, it is unknown how mice will respond to
longer administration periods lasting longer than 28 days. To delineate the onset and progression
of VOMA-induced deficits apart from deficits induced by abstinence, I propose the following:
1) A series of VOMA administration experiments to collect brain tissues at the end of 7, 28 and
44 days of VOMA without any abstinence.
a) This will characterize the onset and progression of neurochemical changes in the brain
that occur as a result of progressively longer periods of VOMA. I hypothesize that
neurotoxicity in tissues will positively correlate with length of VOMA, with increasing
neuroinflammatory responses observed as the time spent in VOMA increases.
b) Alternatively, mice on VOMA could show an unchanged neurochemical profile as a
result of MA-induced D1 activity127, 130-132 and fail to exhibit robust molecular deficits
throughout the course of the study. This finding could provide pivotal information about
the utility of the VOMA model and overall, the long-term effects of voluntary oral MA
on neurochemistry. A measure to assess the feasibility of this proposed experiment will
be by tracking daily consumption. From the studies provided, we know that
neuroinflammation is present in mice when consumption rates are sustained at or above
~5mg/kg MA/day. In mouse populations consuming below this level, alternative
approaches to answer this question should be used.
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i) An alternative approach to delineate the neuroinflammatory response of VOMA apart
from that of abstinence would be to expose mice to bolus injections of approx.
5mg/kg MA/day and per the given study time-course above.
c) Follow-up experiments should assess the cognitive performance of mice given 7 and 44
days of VOMA. These experiments will provide a time-course for behavioral changes
produced by progressively longer exposure to MA via VOMA.

6.2 Mechanisms underlying abstinence-induced changes in behavior and neurochemistry
following VOMA
The studies included into this dissertation have utilized a 2-week (approximately 14 days) or 4week (approximately 28 days) abstinence period to carry out behavioral assessments and prior to
specific tissue collections. Data from Chapter 3 suggests that abstinence can remediate cognitive
deficits produced by MA, despite contradictory neurochemical changes that show activation of
susceptible molecular signaling. It remains unclear what molecular signaling during abstinence
can promote neurodegenerative or neuroprotective pathways in the brain. Thus, to clarify what
molecular pathways should be targeted during abstinence in clinical settings, I propose the
following:
1) A series of VOMA administration experiments to assess efficacy of pharmacological agents
administered during abstinence in preventing the neurochemical changes produced during a
14-day, 28-day, and 44-day abstinence period
a) A series of experiments using NSAIDs (targeting cyclooxygenases) and ERα agonist
estradiol (starting administration right after VOMA) to test the efficacy of these
pharmacological interventions in preventing the negative neurochemical changes
associated with abstinence after MA exposure, such as decreases in DAT, increases in
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PGJ2 levels, COX-2, and others. Control groups will receive no additional treatment for
44-days of abstinence.
b) Follow-up experiments should assess the behavioral changes associated with
administering these drugs during abstinence, with behavioral assessments occurring
during and after the abstinence period
c) Alternatively, we could observe that all neurodegenerative signaling could resolve by the
end of 44 days of abstinence in control groups receiving no NSAID or estradiol
treatment. This could suggest that no pharmacological intervention is necessary for
resolution of these neurochemical deficits and that additional treatment only speeds up
potential recovery of neurochemical deficits. In this scenario, follow-up experiments
should the efficacy of NSAID or estradiol treatment in preventing deficits induced by a
series of low-dose and high-dose challenge exposures of MA, following abstinence. This
follow-up experiment will test the efficacy of pharmacological intervention in reducing
the neurochemical deficits associated with a challenge exposure of MA, as previous
studies have shown that neuroprotection by low-dose MA exposure is eliminated by 31
days after low-dose MA exposure341.
i) Alternative approaches should also be considered as per section 6.1.b above, if mice
consume below 5mg/kg MA/day. Tissue analyses will be feasible from mice that
receive similar doses in order to delineate the effects of compounding
pharmacological interventions, as outlined above.
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6.3 Mechanisms underlying neuroprotection or susceptibility following Escalation VOMA
The last study in this dissertation showed that male mice exhibit protection from MA’s
detrimental behavioral and neurochemical effects as a result of Escalating doses of MA. This
effect was not seen in female mice. Further investigation at the molecular level showed that male
mice showed significant increases in hippocampal estrogen receptor alpha, an effect that female
mice did not show. These results warrant further investigation in order to determine more clearly
the necessity of ERα-to-GSK3β activity to promote neuroprotection in males. To do so, I
propose the following:
1) A series of VOMA administration experiments with an added ERα antagonist manipulation
in male mice to determine the necessity of ERα to promote behavioral and neurochemical
resilience. An initial administration design could see the ERα antagonist delivered at the
start, middle and end of the 28-day VOMA period.
a) These experiments will determine if male mice need to upregulate ERα in order to show
resilience to MA challenges. I hypothesize that male mice co-administered with an ERα
antagonist will show behavioral and neurochemical deficits after VOMA
i) Alternative approaches should also be considered as per section 6.1.b above, if mice
consume below 5mg/kg MA/day. Tissue analyses will be feasible from mice that
receive similar doses in order to delineate the effects of compounding
pharmacological interventions, as outlined above.
2) A series of VOMA administration experiments with an added ERα agonist manipulation in
female mice to determine the necessity of ERα to promote behavioral and neurochemical
resilience in these mice. An initial administration design could see the ERα agonist delivered
at the start, middle and end of the 28-day VOMA period.
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a) These experiments will determine if female mice that are given ERα agonist exhibit
neuroprotection, like male mice have already shown
i) Alternative approaches should also be considered as per section 6.1.b above, if mice
consume below 5mg/kg MA/day. Tissue analyses will be feasible from mice that
receive similar doses in order to delineate the effects of compounding
pharmacological interventions, as outlined above.
The potential pitfalls from these experimental designs include the unknown variable of the 10day escalation period of VOMA. This period, prior to the full-dose and access to MA, could
prove to be a pivotal priming point for mice that enables activation or suppression of
neuroprotective pathways. Thus, to answer this question, I propose the following:
3) A series of Escalation-VOMA administration experiments to collect tissues at 2 days, 4 days,
6 days, 8 days, and 10 days into the Escalation period. This design will enable us to capture
the progression of neurochemical adaptation that mice are going through prior to engaging in
full-access VOMA.
a) These experiments will determine how male and female mice are responding to
escalating doses of MA in the different tissues collected. It will be important to collect a
few brain tissue and potentially a few relevant peripheral tissues (like liver, intestines,
and others) to determine the full scope of molecular changes that mice exposed to
escalation VOMA undergo.
i) Alternative approaches should also be considered as per section 6.1.b above, if mice
do not escalate as well as presented in Chapter 4. In this alternative experiment,
injections of average daily escalating doses should be administered throughout the
10-day escalation period to accomplish the tissue collection design above.
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APPENDICES
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Appendix I. 5HT1b Mutant mice: MA consumption in VOMA

Figure 28. 5-HT1b Knockout mice show different rates of consumption across sexes. Mice
aged 8-16 weeks at the start of VOMA were put through Escalation VOMA. Tracking of MA
consumption revealed the female KO mice consumed significantly less over the 28 days of
VOMA [Two-way repeated measures ANOVA: across gender: F1,9=3.685, p=0.08; across days:
F27,243=9.67, p<0.001; interaction of gender and days: F27,243=2.23, p<0.001]
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Appendix II. Bolus MA increases chronic neuroinflammation after 6 weeks of abstinence

Figure 29. Chronic neuroinflammation after 6 weeks of abstinence following bolus MA.
Ubiquitin and COX-2 significantly increased 6 weeks after bolus (60mg/kg) MA treatment
(*p<.05). Ubiquitin and COX-2 quantified by WB.
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